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Abstract
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a
progressive and ultimately fatal neurological disease that interferes with the normative
functions of the upper and lower motor neurons in the brain and spinal cord. Depression
has been found across disease stages in some ALS patients, but not all. Investigations that
examined the association between physical functioning and depression in ALS patients
produced mixed findings. To date, the role of social problem solving has not yet been
explored in the ALS population. Thus, the current study examined the relationship
between social problem solving, physical functioning, and depression in ALS patients. A
total of71 ALS patients participated in the study. The ALS patients were administered
the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revise, Manual Muscle Test,
Brief Symptom Inventory 18, the Center for Epidemiologic Studies Depressed Mood
Scale, and the Social Problem-Solving Inventory - Revised Short. Data were analyzed
using two separate correlations and one multiple regression. Results from the current
study concluded: (a) clinically significant levels of depression were found in 15 - 32.3%
of the ALS subjects, (b) there was a positive correlation between poor social problem
solving skills and depression, (c) there was a small correlation between poor physical
functioning and depression, (d) bulbar functioning was not correlated with depression,
and (e) negative problem orientation predicted 26.8% of the total variance for depression.
Overall, the results from this investigation demonstrated negative problem orientation not
physical function was a predictor of higher levels of depression in ALS patients. The
implication from this study suggests that empirically supported treatment approaches
such as problem-solving therapy may reduce depression in ALS patients.
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Chapter 1
Introduction

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's
disease, is a progressive and ultimately fatal neurological disease that interferes with
the normative functions of the upper and lower motor neurons in the brain and spinal
cord (Cwik, 2001; Shaw, 2006). An estimated 30,000 individuals in the United States
are living with ALS at one time. Death occurs in approximately 75% of those affected
within 2 to 5 years following the presentation of symptoms (www.alsa.org). The age
range of onset is between 40 and 70, with an almost equal incidence in both genders.
Currently there is no cure for ALS; treatment is focused on slowing the progression of
the degeneration of neurons and improving the overall quality of life.
It is generally assumed by many health care professionals and caregivers that

depression is commonplace among individuals diagnosed with a terminal illness
(Rabkin, Glenn, Wagner, & Del Bene, 2000). Although the psychological impact of
ALS can affect the patient's mood, depression may be less common than initially
believed. Research findings thus far suggest that depression at the clinical and
subclinical levels may be present in some, but not in all, individuals diagnosed with
the illness (Felgoise, Chakraborty, Bond, Bremer, Walsh, & Simmons, 2005, 2005;
Ganzini, Johnston, McFarland, Tolle, & Lee, 1998). Furthermore, investigations
examining the association between physical functioning and depression in ALS
patients have produced mixed findings (Goldstein, Atkins, Landau, Brown, & Leigh,
2006).
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Social problem-solving skills have been shown to predict and mediate
depression in persons with other chronic medical illnesses, such as cancer (Nezu et
aI., 1999) and spinal cord injury (Elliott, 1999). However, the role of social problem
solving skills in depression for ALS patients has not been explored. To address this
impOliant gap in the literature, this study aims to examine the relationship between
social problem solving, physical functioning, and depression in ALS patients. If
social problem-solving skills are shown to be predictive or influential of depression in
the ALS population, then existing empirically supported, manualized treatments using
social problem-solving skills to decrease depression for other medical populations
could be modified and adapted to meet the needs of persons with ALS. Therefore,
understanding depression and the role of social problem-solving skills as they relate
to physical flU1ctioning in persons with ALS may be important for treatment plmming.

Statement ofObjectives

1.

Determine if there is a relationship between poor social problem solving
and depression in ALS patients;

2.

Determine ifphysical functioning predicts depression in ALS patients;

3.

Examine the interaction between social problem solving, physical
functioning, and depression.

Amyotrophic Lateral Sclerosis

The medical te1111 amyotrophic lateral sclerois (ALS) was derived from the
Greek term amyotrophi:c a stands for no or negative, 111yO references muscle, and
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trophic is nourishment. When the terms are brought together, they signify "no muscle

nourishment." Lateral refers to the region ofthe spinal cord in which the nerves send
messages to specific muscle groups; sclerosis is the breakdown or hardening that
occurs in the spinal region (www.alsa.org).

Prevalence.

ALS is a debilitating and eventually fatal progressive neurodegenerative
disease, which produces rapid muscle weakness, paralysis, and respiratory failure
(Brooks, 1996; Rabkin et al., 2000). It has been estimated that ALS is diagnosed in
11100,000 to 21100,000 individuals annually. In the United States, approximately
5,600 cases are newly diagnosed each year, with an estimated 75% of individuals
dying from complications related to the disease within 2 t05 years of diagnosis
(www.alsa.org).
The average age of onset is 40 to 70, with a mean age of 55. Generally, those
diagnosed with sporadic ALS tend to experience the onset of disease between the
ages of 58 and 63, while familial cases tend to develop in those between 47 and 52
years old. In addition, individuals in their 20's and 30's have also been diagnosed,
though it is less common (www.alsa.org). ALS has a 1.7:1 male: female ratio,
meaning that men are at an increased risk of developing ALS, but the gender ratio
diminishes with older age (Haverkamp, Appel, & Appel, 1995; Cwik, 2001).
Currently, 93% of reported cases diagnosed are of White individuals. For the most
part, ALS is believed to affect individuals equally worldwide after controlling for
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culture, etlmicity, geographic location, enviro1Ullental conditions, and nutritional
differences (Cwik, 2001; www.alsa.org).

Classification.
ALS is classified as a neurodegenerative disease however; it is not entirely
understood what facilitates the degeneration course. As a result, a primary
classification system was developed for ALS based on three categories: clinical
syndromes, mode ofacquisition, and degree ofdiagnostic certainty (Cwik, 2001).
ALS clinical syndromes vary depending upon the clinical presentation, symptoms,
and prognostic indicators. Classic ALS is discernible by damage to the upper and
lower motor neurons. When these two motor neurons are damaged, it causes the
individual to experience muscle spasticity, exaggerated or diminished reflex
movements, and weakness and/or degeneration of the muscle. However, some
individuals with ALS may present with damage to only the upper motor neuron, only
the lower motor neuron, or damage only in one muscle region.
The mode ofacquisition is essentially the way ALS develops. Generally, ALS
is sporadic,familial, or Guamanian. Sporadic ALS is the most common and is
diagnosed in 90% to 95% of all cases in the United States. The characteristics ofthis
include a break- down of the upper and lower motor neurons. A great majority of
ALS patients with sporadic ALS present with limb-onset disease, 25% with bulbar
onset disease, and 8% to10% with lower motor neuron decline (Mitsumoto, 1997).
Familial ALS is generally diagnosed in 5% to 10% of cases. A small percentage of
individuals diagnosed with familial ALS were fOlU1d with a defect in the gene for
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superoxide dismutase (Siddique, Nijhawan, Hentati, 1996; Cwik, 2001).
Lastly,Guamanian ALS was detected and named based on the high number of cases
reported in Guam and other U.S. Territories in the 1950s (www.alsa.org).
The degree ofdiagnostic certainty refers to how a diagnosis of ALS is
determined. Unfortunately, ALS has yet to be diagnosable based on one laboratory
test finding. Instead, the diagnostic formulation is determined by physical symptoms,
laboratory tests, differential diagnosis, and symptom onset during the disease
progression (Cwik, 2001).

Diagnostic criteria.
Prior to receiving a formal diagnosis of ALS, patients tend to seek medical
attention in the early phases of the disease for noticeable muscle weakness in an outer
extremity such as an arm or leg (Mitsumoto, 1997,2001). They frequently report
problems with buttoning clothing, picking up or carrying objects, unsteady gait,
tripping or stumbling while walking or running, difficulty climbing stairs, foot
dragging, struggling with getting up out of a seated position, muscle cramps, fatigue,
and/or weight loss (www.alsa.org).
The course of ALS often begins to manifest in one of four muscle regions
(bulbar, cervical, thoracic, and lumbosacral). Each region controls different muscle
movements. The bulbar region includes the facial, tongue, jaw, and larynx muscles.
Twenty percent to 25% of individuals diagnosed with ALS present with bulbar
symptoms (Mitsumoto, 2001). Bulbar weakness has also been found to be more
prevalent in females and in those aged 70 and older (Haverkamp, Appel, & Appel,
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1995). The cervical region includes muscle movement in the diaplU'agm, hands, and
arms. Approximately one third initially develop wealmess in the aml (MitSlU110tO,
1997,2001). The thoracic region controls the abdominals as well as back muscles.
Lastly, the lumbosacral region includes legs, feet, abdominal, and back muscles
(Mitsumoto, 1997). It has been estimated that one third of ALS patients present with
wealmess in the leg (Mitsumoto, 1997,2001). Though less COllU110n, some
individuals experience diffuse weakness in the bulbar, ann, and leg muscles. In
general, ALS tends to progress asymmetrically early on before it manifests into
contralateral limbs. Muscle wealmess tends to be a slow and steady progression.
The Revised El Escorial World Federation of Neurology (Brooks, 1994;
Forbes, Colville, & Swingler, 2001) are the internationally recognized diagnostic
criteria used to detemline the presence of ALS. In order to meet these criteria,
historical information peliaining to symptom onset, disease progression, past medical
history, family history, sphincter problems, mental status, and sensory complaints
need to be examined (Mitsumoto, 1997). In addition, neurologic examinations are
used to determine the functionality in the upper motor neuron and lower motor
neuron reglOns.
Upper motor neuron damage can cause symptoms including: (a) loss of
dexterity, which affects voluntary and reflex movements of fine motor skills, as a

result, ALS patients may experience stiffness, delayed movement, or clumsiness in
fingers, feet, lips, or tongue, (b) loss ofmuscle strength, the primary sign and
symptom of ALS and generally less severe in the upper 111otor neuron as compared to
the lower motor neuron, (c) spasticity, which is described as muscle tension, (d)
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pathologic hyperreflexia, an exaggerated reflex muscle response, (e) pathologic
reflexes, defined as abnormal reflex responses, and (f) spastic bulbar palsy,
weakness in the bulbar region that produces problems with speech, chewing, and
"

swallowing. In addition, ALS patients tend to experience emotion dysregulation such
as impulsive crying and laughter (Mitsumoto, 2001).
Lower motor neuron damage can cause symptoms including: (a) loss of

muscle strength, which is generally more severe in the lower motor neuron and
affects the outer extremities, (b) muscle atrophy, a decreased muscle size occurring in
the hands, forearm, lower leg, and foot muscles, (c) muscle hypotonicity, decreased
muscle resistance, which causes the muscles to become motionless, (4)fasciculations,
muscle twitches that tend to occur often, and (e) muscle cramps, involuntary muscle
contractions that occur across various muscle regions including the calf, thigh, arms,
abdomen, and neck (Mitsumoto, 2001).
In terms of cognitive functioning and ALS, studies have identified cognitive
decline in upwards of one third to one half of ALS patients diagnosed with sporadic
or familial ALS. Researchers have found more than one type of cognitive impairment
in this population. Frontotemporal dementia is the most commonly found and
researched form of dementia detected in ALS patients (Ringholz, Appel, Bradshaw,
Cooke, Mosnikm, & Shultz, 2005; Rippon, Scarmeas, Gordon, Murphy, Albert,
Mitsumoto et aI., 2006; Robinson, Lacey, Grugan, Glosser, Grossman, & McCluskey,
2006; Wheaton, Salamone, Mosnik, McDonald, Appel, & Schmolck, 2007).
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Diagnostic categories.
The diagnostic categories of ALS include d~finite ALS, probable ALS,

probable ALS - lab supported, possible ALS, and suspected ALS.

D~finite

ALS is

based upon the clinical detection of lower and upper motor neuron degeneration in
the bulbar as well as two additional regions or in three spinal regions. Probable ALS
is based upon the clinical detection of lower and upper motor neuron degeneration in
a minimum of two regions. Probable ALS - Lab Supported includes both upper motor
neuron and criteria for only one region of the lower motor neuron or a minimum of
one upper motor neuron region and electromyography nerve blockage in two or more
outer extremities. Possible ALS is based upon the clinical detection of lower and
upper motor neuron degeneration in only one region or detection in only the lower or
only the upper neurons.

Suc~pected ALS is

diagnosed when it is only detected in two or

more regions of the lower motor neuron (Brooks, 1994; Forbes, Colville, & Swingler,
2001).

In addition, four categories were developed to classify the types of progressive
lower and upper motor neuron degenerations: Sporadic ALS, which occurs in
isolation; Coexistent sporadic ALS, which presents intenllittently and co-occurs with
other preexisting diseases in conjlUlction with ALS; ALS-related syndromes, which
occur with the epidemiologic flndings of the progression of ALS; and ALS variants,
which occur with clinical, genetic, or epidemiological flndings that parallel the
disease (Brooks, 1994).
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Symptom management.

Ongoing ALS research continues to search for a cure; however, none has been
found thus far. For now, ALS patients are encouraged to receive treatment at an ALS
specific clinic close to home. In this setting, ALS patients are able to receive
comprehensive treatment il'om a team of professionals including one of more of the
following: neurologist, nurse coordinator, physical therapist, occupational therapist,
speech pathologist, dietitian, and social worker. A comprehensive treatment approach
reduces the frequency of visits, but may increase the length of time spent in the clinic
(Jacobs & Mitsumoto, 2001).
Presently, the medication riluzole is the only FDA-approved disease-specific
treatment available in the United States used to decrease the loss of muscle strength,
prolong survival rates by a couple of months, and increase the overall life span of
some individuals with ALS (Bensimon et aI., 1994). With only one FDA-approved
medication on the market, ALS patients have the option to receive treatment of their
symptoms of the disease. Some common ALS symptoms include: muscle cramps and
spasms, excessive crying or laughter, urinary urgency or frequency, excessive
saliva, thick phlegm/post nasal drip, jaw quivering/clenching, laryngospasm, acid
reflux, nasal congestion, sleep disturbance, depression/anxiety, shortness of breath,
pain, nausea, agitation/anxiety, communication difficulties, and terminal
management (Gelinas, 2001). The detailed information describing symptoms and
treatment options is beyond the scope of this study.
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Physical Functioning
In the literature, the findings on the association between physical functioning
and mood have been mixed (Goldstein, et al., 2006). The following studies reflect the
absence of a relationship between physical functioning and mood. Rabkin et al.
(2000) examined depression and distress related to the degree of ALS disease
progression and functional impail111ent in 56 ALS patients, as measured using several
questionnaires. The study concluded that distress and depressive symptoms were not
associated with time, physical manifestations, or progression of ALS.
Norquist, Kenkinson, Fitzpatrick, Swash, and the ALS-HPS Steering Group
(2003) examined factors predictive of physical and mental health based on health
status from an assessment at baseline and 12 months later. One thousand one hundred
eighteen subjects completed the SF-36, the General Well-Being Scale, the Caregiver
Strain Index, and the Amyotrophic Lateral Sclerosis Functional Rating Scale at
baseline, while 918 of the initial subjects also completed the same measures 12
months later. Results from this study found while physical functioning declined by
15% over the 12-month period, no significant changes to mental health scores were
identified.
In another study (Robbins, Simmons, Bremer, Walsh, & Fischer, 2001) of 60
subjects (53.3% male and 46.7% female, with a mean age of 58.5), researchers
examined physical functioning and quality of life using self-report quality of life
measures, including the McGill Quality of Life measure and the ALS Functional
Rating Scale, at baseline, 3-month and 6-month intervals. Results of this study
revealed that while physical functioning declined patients' quality of life remained
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stable. Neudert, Wasner, and Borasio (2004) also examined quality of life factors
specifically related to physical functioning and psychosocial factors during the
progression of ALS. The researchers concluded that as the disease progressed,
physical functioning declined while psychosocial factors remained stable.
Conversely, some research studies have found an association between aspects
of physical functioning and mood. Hillemacher et al. (2004) examined the factors that
predict or int1uence depression in ALS patients. F01iy-one ALS patients completed a
self- report depression questi01maire and the Amyotrophic Lateral Sclerosis
Functional Rating Scale. Results did not find a significant relationship between
decreased general physical ability and depression. However, the researchers did
identify reactive depression as a result of bulbar and respiratory symptoms.
In another investigation, Goldstein et al., (2006) explored predictors of
psychological distress and low self-esteem and to determine whether these change
over time in ALS patients. Fifty ALS patients participated in the study by completing
questiormaires during the first interview, 32 participated for the second interview, and
26 participated in the third interview. The questi01maires completed were the Close
Persons QuestiOlmaire, Marital Intimacy Scale, ALS Severity Scale, Sickness Impact
Profile, Emotional Liability Questi01maire, the Dysexecutive Questionnaire, the Short
Inventory of Minor Relapses, Hospital Anxiety and Depression Scale, and the Self
esteem Scale. Results from the first interview found bulbar impail111ent predicted
psychological distress.
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Psychosocial Considerations

In general, many patients with a chronic medical condition are able to adjust
adequately to psychosocial aspects surrounding their illness. Meanwhile, an estimated
20% to 25% experience psychological distress secondary to their health status (White,
2001). The potential for psychological distress associated with chronic illness can
result from the gradual onset, lengthy duration, progressive decline over time, unclear
diagnosis and prognosis, absence of a cure, and symptom severity (Holman & Lorig,
2000). Often chronic illness signifies a lifestyle change from independent living
toward physical, emotional, and financial dependency upon others.
Developing a chronic medical condition is considered a major life event.
When this occurs, individuals become more susceptible to psychological
vulnerabilities. Unlike other chronic medical conditions such as cancer or spinal cord
injury that mayor may not be life threatening, ALS is a progressively debilitating and
fatal illness which may produce its own unique psychological vulnerabilities.
Psychosocial stressors found among ALS patients tend to become more pronounced
during different phases of the disease progression and may encompass changes within
social interactions, spiritual andlor religious beliefs, mood fluctuations, and lifestyle
adjustment (Nelson, Trail, Van, Appel, & Lai, 2003).
Psychosocial palliative care addresses how ALS patients respond to the
disease-related stressors. The core aspects of psychosocial palliative care include:
attachment, loss, meaning, and equity (Sheldon, 1997). While these core aspects are
not unique to ALS, an emphasis is often placed on the disease-specific elements ALS
patients often encounter. Psychosocial palliative care begins as soon as the patient is
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formally diagnosed with ALS and continues tlu'ough the progression of the disease.
Some of the more distinct psychosocial stressors in ALS patients relate to hope, loss,
control, and outside support (Gallagher & Momoe, 2006).
Patients are inf01111ed about their ALS diagnosis by their neurologist. The
diagnosis, prognosis, and treatment options are generally presented in a private of1ice
setting while in the company of family. At this stage, the goal of the neurologist is to
provide honest, accurate, and detailed infomlation. The tone of the discussion is calm,
empathic, hopeful, and supportive. Given the disease course, the neurologist is careful
not to overwhelm the patient with too much infomlation when first leaming of their
condition. Instead, written material is provided with the intention that the patient will
read about ALS at their own pace, with their loved ones, and after the initial shock of
their diagnosis decreases some. The patient is also encouraged to contact members of
the ALS multidisciplinary team with questions and for ongoing support (Gallagher &
Momoe, 2006).
Hope has been defined as an ilUler power or strength that can enhance lives
and facilitate individuals to look beyond their pain, suffering, and turmoil (Urquhart,
1999). A research study investigated hope in cancer and motor neuron patients and
identified factors that encourage and discourage hope (Buckley & Helih, 2004). This
study concluded hope was comprised of several factors including: intelversonal
cOlmectedness, spirituality, goal setting, maintaining independence, positive
relationships, self-worth, humor, personal attributes, and positive memories.
Altematively, factors of hopelessness included: abandolUllent, social isolation, loss of
independence, loss of control, and devaluation of personhood. Being able to assess
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for the degree of hope often begins when the neurologist informs the patient of the
diagnosis, prognosis, and treatment options. The goal is to understand what hope
means to the patient, what helps to sustain their hope, what causes them to lose hope,
and how hope changes during the course of the disease. Ga11Zini et al. (1998) found
that ALS patients with suicidal thoughts experienced greater hopelessness when
compared to ALS patients without suicidal thoughts.
Tlu'oughout the course of the disease, ALS patients experience varying
degrees of loss (Gallagher & Monroe, 2006). This may be related to physical
challenges such as age of onset, severity of symptoms, length of illness, and rate of
physical decline. Another f01111 of loss includes isolation from family, friends,
attending events, going to work, and interacting with nature. Additional losses may
include loss of traditional role, financial concerns, or restrictions in leisure activities.
ALS patients' sense of control varies across patients and may change on a
daily basis. Control is assessed early on by the multidisciplinary team in order to
identify potential response patterns as the disease progresses. These patterns are
monitored and addressed as needed. One approach in maintaining healthy control is
to continually reinforce an internal locus of control rather than an exte111al one. An
example of this is when the patient is fonnally diagnosed with ALS. It is during this
time the neurologist discusses with the patient what he/she should anticipate
happening and encourages the patient to become part of the decision-making process
when considering treatment options (Gallagher & Monroe, 2006).
Aside from the ALS multidisciplinary team, the ALS patient's support
netwOl'k, generally comprised of a caregiver, family members, and friends, is a crucial
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element in providing physical, emotional, and financial support during the disease
progression. While the support network helps address some of the psychosocial
stressors the ALS patient is confronted with, it can also pose its own set of stressors.
Family members and caregivers described their experience of daily support as a
cyclic process in which their daily responsibilities include committing to take care of
everyday tasks, tackling unexpected demands and crisis situations, problem solving,
asking for additional help at times from others, occasionally taking a break, and
relying heavily on hope and courage to make it through each day (Kuckelman-Cobb,
Reclding, & Fernengel, 2001).
Outcome findings from the ALS Patient Profile Project (McDonald, 2001)
suggested eight key areas are important in order maintain psychological,
interpersonal, and spiritual well-being and self-esteem while living with ALS. First,
maintain hope that life can still be meaningful and worthwhile despite living with an
incurable disease. Second, use inner strength, meaning, and purpose to live each day.
Third, maintain a nurturing support system. Fourth, shift focus from disease-related
symptoms to focusing in the present and share meaningful experiences with loved
ones. Fifth, develop a respectful relationship with others and be comfortable
expressing thoughts and feelings with them. Sixth, develop and maintain family and
social activities for the ALS patient to participate in. Seventh, utilize support from the
multidisciplinary team. Eighth, pursue treatment or counseling if necessary for ALS
patient, caregiver, or family member.
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Coping, Adaptation, and Emotional Distress
Coping has been described as a process used to manage emotional or
cognitive distress associated with diseases (Lazarus, 1984). Individuals with clu'onic
illness and/or disabilities (CID) often experience stress, crisis, loss and grief, body
image distortions, negative self-perception, stigma, uncertainty, unpredictability, and
a compromised quality of life more frequently then non medical populations. Specific
coping characteristics, such as state and trait determinants, degree of control, locus of
control, affect regulation, cognitions, and behavior styles have a direct relationship
with individual coping strategies.
In the CID literatme (Tobin, Holroyd, Reynolds, & Wigal, 1989; Livneh &
Antonak, 2005), two types of coping strategies have been identified. First,

disengagement coping, which is a maladaptive means of coping tlrrough the use of
avoidance, passivity, denial, self-blame, blaming of others, and substance abuse.
Second, engagement coping is an adaptive, direct, focused, goal-oriented means,
which incorporates problem solving, plmming teclmiques, and the ability to utilize a
support network style. Among these two strategies, researchers found engagement
coping improved overall well-being, acceptance of illness, and adaptability.
Hecht et al. (2002) examined the subjective experiences of patients with ALS
to better understand how these individuals cope. In their study, 41 patients diagnosed
with probable or confimled ALS using the revised World Federation ofNemology
ALS criteria, with disease dmation of 16 months and a median ALS Functional
Rating Scale score of25, agreed to respond to three subjective questions and
complete a self-repOli depressionmeasme on two occasions. The subjective questions
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and most common responses included the following: (a) "In your personal
experience, what are the worst aspects of the disease?" The most common responses
were "reduction of speech," "reduction of mobility," "lmowledge of poor prognosis/'
and "becoming dependent on other person." (b) "Who or what most efficiently
lightened the burden of these aspects?" The most common responses included "the
family," "unspecific coping mechanisms" (i.e., "thinking positive" and "teclmical
aids"); (c) "Who or what could help you in addition?" The most common responses
included "more effective therapy" and "better technical aids." For all three sUbjective
questions, the same responses were ranked similarly upon second administration.
When these same subjects were asked to complete the Trierer Coping QuestiOlmaire
(TCQ), results noted religion as the most common and strongest mode of coping and
the recurring theme of family suppOli to be a maj or benefit to those diagnosed with
the disease.
In addition to coping styles, adaptation is also an impOliant consideration with
ALS patients because unlike other chronic illnesses, the course of ALS is one that
requires the individual to continually adjust to lifestyle changes (Mitsumoto &
Munsat, 2001). Adaptation is defined as patients' ability to actively accept their
prognosis, the ability to accommodate both their enviromllental demands and
subjective desires, and possessing the skills to lea11l how to reconstruct their lives in a
positive maImer (Livneh, 2001). Individuals who are unable to adapt in a functional
way tend to become dependent on others, feel helpless or hopeless, and may be in
denial of their prognosis.
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Unlike other chronic illnesses, such as cancer and spinal cord injury, ALS
patients are faced with a disease sequence that includes progressive muscle decline,
physical limitations, lack of curative treatment options, and death. So while other
illnesses such as cancer may ultimately lead to death, there are treatments available to
slow down or eliminate the disease progression in a greater propOliion of those
inflicted. This is not the case with ALS. While some treatment approaches with
medication or specific therapies appear to prolong survival via slowing disease
progression during the early phases ofthe illness, there is no treatment available to
slow the disease in the later stages or eliminate ALS altogether (Gelinas, 2001).
Livneh (2001) stated that the ability to adapt to life with a chronic illness and
disability is a predictor of overall quality of life. This idea is based on several
hierarchical domains, including intrapersonal functioning (health status,
psychological state, satisfaction, view of self), interpersonal functioning
(interpersonal relationships, family dynamics, marriage and intimacy ,and peer
interaction), and extrapersonal flUlctioning (education, employment, and recreation).
Adaptation styles in ALS patients are often detected during the early phase of the
illness. Newly diagnosed individuals tend to experience anger, denial, bargaining,
depression, anxiety, and acceptance. They also may interpret the news with feelings
of intolerance or sadness or view ALS as an 0ppOliunity for a spiritual journey. For
this reason, many ALS interdisciplinary clinics strongly recommend that the patient
utilize their support network upon initial diagnosis and tlu'ough the course of the
illness (www.alsa.org).
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Generally, the best predictor of one's ability to adjust to life with ALS is
based upon how individuals were able to adjust to past lifestyle changes. A qualitative
research study (Young & McNicoll, 1998) identified two common themes regarding
positive adaptation strategies. Participants in this patiicular study reported that the
key to adapting occUlTed through humor and a positive outlook. Moreover, these
same paliicipants also described additional effective adaptation strategies, including
the use of cognitive reappraisal techniques to help them accept what they could
control in their life versus what was out of their control, looking for alternative ways
of how to perceive their situation, reframing teclllliques, thought control, looking for
the positives, living in the here and now, and using imagery.
Trail, Nelson, Van, Appel, and Lai (2004) investigated emotional distress in
ALS patients by examining physical domains (muscle weakness, mobility problems),
psychosocial domain (financial stress, depression, lack of family support), and
existential domains (worry about the future, loss of faith in religion, worries about
illness progression). Findings suggested that 1110st subjects expressed concerns central
to existential and physical domains. In addition, the investigators found the three most
common stressors reported by ALS subjects were (a) wonies about the illness
progression and dependency issues, (b) problems speaking, and (c) muscle wealmess.
This study concluded that specific stressors have the potential to trigger adaptive or
maladaptive coping styles.
Heijmans (1999) proposed that patients who view clu'onic illness as serious,
lUu'emitting, and uIU11anageable are more likely to become passive and experience
increased limitations, more social discord, and mood ±1uctuations. Lacroix et al.
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(1991) suggested schematic processing can provide an understanding of how
cognitive processing influences the patient's interpretation ofthe disease diagnosis
and progression. This concept of schematic processing may provide a better
understanding of the mechanisms by which ALS patients experience the process of
coping, adaptation, and emotional distress, as compared to others with a medical
illness.

Depression and ALS
Depression in individuals with a clu'onic illness has often been associated with
distress due to physical limitations, loss of independence, decrease in pleasurable
activities, denial, pessimism, communication difficulties, swallowing, breathing, and
disease progression (Hogg, Goldstein, & Leigh, 1994; Rabkin et al., 2000;
Hillemacher et al., 2004). Many health care professionals, caregivers, family, and
friends assume depression is conmlon among individuals diagnosed with an incurable
and progressive disease such as ALS. Even though the psychological impact of ALS
can affect the patient's mood, depression may be less conU110n than once thought.
Major depressive disorder (MDD), as it is defined by the American
Psychiatric Association's diagnostic and statistical manual o/mental disorders,
fourth edition, text revision (DSM-IV) (American Psychiatric Association, 2000),
states the individual must experience five out of the nine criteria for a minimum of2
weeks and report a depressed mood and/or decreased interest in once pleasurable
activities. Additionally, the individual experiences a clinically significant level of
emotional distress, causing possible impairment to daily functioning. The level of
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depression may vary from mild to severe, be present with or without psychotic
features, or be considered as recurring or in remission. The DSM-IV-TR also states a
diagnosis is not warranted if the symptoms are directly associated with substance or
drug abuse, side e±Iects from prescribed medication or medical treatments, or
exposure to toxic chemicals.
The prevalence of depression in the ALS population is difficult to estimate.
This may in part be the result ofval'iations (age, stage of disease, psychiatric history)
within subject pools as well as varying methodologies and measures used to assess
symptoms (Bungener, PiquaI'd, Pradat, Salachas, Meininger, & Lacomblez., 2005;
Rabkin et aI., 2005). Another consideration is that while ALS patients tend to
experience elevated levels of depression when compared to non psychiatric
populations, not all experience depression. This means that some might experience
clinical depression, subthreshold depression, or no depression (Ganzini et aI., 1998;
Rabkin et aI., 2000; Felgoise et aI., 2005).
In a longitudinal study examining 80 late-stage ALS patients, researchers
fOlUld that less than 10% of subjects presented with major depression, while other
subjects were reported to experience transient depressive symptoms. Furthermore, the
researchers did not find depression and neamess of death to be concurrent with all
subjects (Rabkin et aI., 2005). Consistent ±Indings were also established in a study
using the Center for Epidemiologic Studies Depressed Mood Scale (CES-D) self
report, in which no c011'elation between disease duration and lowered scores of
psychological well-being were present (Lou, Reeves, Benic, & Sexton, 2003).
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In another investigation by Rabkin et al. (2000), 56 patients were examined
over time tlu'ough clinical interview and questiOlmaires to assess depression as well as
other disease-related considerations in an ALS-specific subject pool. The prevalence
rates in the study's subject pool consisted of the following: 88% no clinical
depression, 2% CUlTent major depressive disorder, 7% subtlu'eshold major depression,
and 4% minor depression. After 5.5 months, subjects were reevaluated using the same
measures. Results did not find increased levels of depression over time for the sample
as a whole. When subj ects were asked if a mood change occulTed, 15 remained non
depressed, 1 remained depressed, and 4 repOlied changes to their mood (2 improved
and 2 worsened). Overall findings suggest that distress and depressive symptoms
were not associated with time since diagnosis, changes in physical state due to the
illness, or illness progression.
In another investigation (Ganzini, Jolmston, & Hoffman, 1999) which
examined perceived suffering, pain, overall quality of life, depression, and
hopelessness in ALS patients, the researchers found 11 out of 100 patients met
criteria for depression based upon the DSM-IV criteria. Moreover, Hillemacher et al.
(2004) compared depression scales, the ALS Functional Rating Scale, disease
duration, gender, age, and level of education in 41 ALS subjects. The results from this
study did not support an association between depression and general physical
functioning. The study did, however, find reactive depression upon initial diagnosis
and with conununication and breathing difficulties.
With prevalence of depression still unclear, research findings show some ALS
patients are experiencing subtlu'eshold depression or clinical depression. Based on
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this data, the European Federation of Neurological Societies (EFNS) task force
identified pharmacotherapy treatment for depression using the ALS Care Database.
The listing of antidepressant medication consisted of paroxetine, fluoxetine,
amitriptyline, and seliraline, with amitriptyline providing the greatest amount of
symptom relief (Andersen et aI., 2005). The database also revealed that of the ALS
patients presenting with depression, less than half were treated with pha1111acotherapy
and data was unavailable for those receiving psychotherapy.
In te1111S of psychotherapy research, researchers examined optimism as it
related to well-being and depression in ALS patients and their caregivers through
mediation factors of appraisal and coping style. This study found ALS patients and
their caregivers who were able to give up control were more optimistic and less
depressed (Mock, Gabriel, TU111bull, & Wethington, 2004). Other studies attempting
to understand the mechanisms of adaptive coping found optimism, sense of control,
use of humor, utilizing a suppOli network, cognitive reappraisal, reframing, and
intellectual stimulation increased ALS patients' ability to accept their diagnosis and
prognosis (Young & McNicoll, 1998; Trail, Nelson, Van, Appel, & Lai, 2004).

Social Problem Solving TheOlY

Social problem solving theory is understood by explanation of the following
two models: the relational model of stress (Lazarus & Folkman, 1984; D'Zurilla &
Nezu, 1999) and the relational/problem-solving model of stress (D'Zurilla & Nezu,
1999; Nezu, D'Zurilla, Zwick, & Nezu, 2004). The first model, the relational model
of stress, (Lazarus & Folkman, 1984) defines stress as a type of person-environment
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association in which demands are appraised by the person to detennine if they are
equipped with sufficient coping resources and whether their well-being is at risk.
According to this model, a person experiencing a stressful event greatly influences
the quality and intensity of their response to stress through two processes: coping

appraisal and coping.
Coping appraisal is the process by which a person determines the meaning or
personal significance of a stressful encounter with the envirolllilent. The two types of
appraisal include primary appraisal, which refers to the self-evaluation and
significance of the situation and its impact on overall well-being. Secondary appraisal
refers to the person's appraisal of his/her coping choices and resources.

Coping refers to the various cognitive and behavioral activities by which the
person attempts to manage stressful situational demands as well as the emotions that
may be generated. The two primary coping methods include problem-focused coping
and emotion-focused coping. The first method, problem-focused coping, refers to
improving a stressful situation, while the second method, emotion-focused coping,
refers to the ability of regulating emotions resulting from the situation. Problem
focused coping often occurs when stressful situations are appraised as changeable or
controllable, while emotion-focused coping generally occurs in situations appraised
as unchangeable or uncontrollable.
The relational model of stress defines problem solving as a type of problem
focused coping in which problem-solving goals are equated with control over
envirolUllent or mastery goals. Problem-solving is considered maladaptive when
stressful situations are perceived as unchangeable or uncontrollable.
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The second model, relational/problem-solving model of stress (D'Zmilla &
Nezu, 1999; Nezu, et al., 2004), maintains the fundamental frame work of the
relational model of stress, but also incorporates a greater emphasis on problem
solving. As such, the second model describes stress as a fWlction of the reciprocal
relationship across three variables: stressful life events, emotional stress response, and
problem-solving coping. StressfiJI life events are life experiences to internal and

external demands that require readjustment. The two types of stressful life events
consist of a major negative event and a daily problem. A major life event is a global
life experience that generally demands readjustment. Examples of this include:
divorce, job loss, major medical illness, injmy, or death. A daily problem is a specific
life experience dming which there is perceived imbalance between adaptive demands
and a sufficient coping response.
Emotional stress response is the initial emotional response (negative or

positive) to a stress life event based on appraisal and coping. Negative emotional
responses tend to occm when the problem is appraised as a direct tln'eat to well-being,
there is self-doubt in ability to effectively cope with situation, or the individual
engages in inefIective or maladaptive coping. Alternatively, positive emotional
responses occm when the problem is perceived as a challenge or opportunity, the
individual believes they have the capability to cope effectively, and they are utilizing
effective coping response. Lastly, the relational/problem-solving model of stress
identifies problem-solving coping to include problem-focused goals, emotion-focused
goals, or both, based on the specific problem and how it is defIned and appraised.
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The relational/problem solving model of stress (D'Zurilla, Nezu, & Maydeu
Olivares, 2004) defines social problem-solving as a self-directed cognitive-behavioral
process individuals use in order to identify possible effective or adaptive coping
strategies when problems occur in daily living. Social problem solving encompasses
several domains, including impersonal problems (e.g., insufficient finances),
intrapersonal problems (e.g., cognitive, emotional, behavioral, or health-related
concerns), interpersonal problems (e.g., relationship problems, marital discord,
family-related concerns), and societal problems (e.g., crime, racial discrimination).
The definition of problem is "any life situation or task, either present or in the
near future, that requires a response for adaptive functioning but no effective response
is immediately apparent or available to the person or people confronted with a
situation, because of the presence of one or more obstacles" (D'Zurilla et al., 2004, p.
12). Such obstacles may include uncertainty, unpredictability, skill deficits, or limited
resources. A problem could be time limited, a sequence of events, or chronic.
Moreover, the obstacles to problem resolution may stem fl'om within the individual or
may be a product of the envirolUllent.
A solution is a cognitive or behavioral response pattern that is the product or
outcome of the problem-solving process when it is applied to a specific problematic
situation. To reach an effective solution means that the individual is able to achieve
his or her problem-solving goal while maximizing positive consequences and
minimizing negative consequences.

Problem solving and solution implementation are two additional aspects of
the social problem-solving model (D'Zurilla & Nezu, 1999; D'Zurilla et al., 2004).
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Problem-solving is the act of searching for solutions to specifIc problems, and
solution implementation is defined as the act of executing those solutions within
problematic situations. Problem-solving skills are considered to be general, while
solution implementation skills tend to vary based upon the type of problem and
solution.

The social problem-solving model.
The original model of social problem solving was first developed by D' Zurilla
and Goldfried (1971) and later modif1ed by D'Zurilla and Nezu (1999). According to
the revised model, there are two mechanisms of problem-solving: problem

orientation and problem-solving proper. Problem orientation is a relatively stable
cognitive-emotional schema that reflects the thoughts and feelings of an individual in
te1111S of problem development and one's ability to solve problems. Furthermore,
problem orientation is a motivational component of the problem-solving process.

Problem-solving proper is a rational method of searching for an effective or adaptive
solution to a specific problem via the use of problem-solving strategies. Problem

orientation is a general awareness of one's attribution style, perception, self-efficacy,
appraisal of problems, and one's ability to problem solve (D'Zurilla & Nezu, 1999).
Positive problem orientation tends to evoke a positive or constructive approach in
which the individual views a problem as a challenge, exudes optimism and/or
confidence in their ability to solve a problem, exercises patience during the problem
solving process, and maintains focus and motivation to solve the problem at hand.
Negative problem orientation often presents as low self-efficacy, negative affect, low
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frustration tolerance, anticipation of a negative outcome, and a lack of motivation in
the presence of a problem.
In general, problem orientation is comprised of a few factors. The first factor,
problem perception, is the awareness and intention to address problems as they

develop. The second factor, problem attribution, is the meaning the individual
attaches to the problem. Individuals who possess a positive attribution style may
deem the problem changeable and may not attribute the problem to personal
limitations. Alternatively, individuals with a negative attribution style are likely to
identify the problem as fixed or unchangeable and attribute its occurrence to their
own perceived deficits. The third factor, problem appraisal, tends to be based upon
individual attribution style and self-efficacy, i.e., when a problem develops, some
individuals will see it as either an oppOliunity for growth and development or as a
threat.
Problem-solving proper is a problem-solving skill set that increases the
likelihood that individuals will be able to effectively solve problems. D'Zurilla and
Nezu (1999) identify four skills in the set: problem definition and fornmlation, the
generation of altemative solutions, decision making, and solution implementation and
verification. The first skill, problem definition and formulation, is the ability to
identify a problem, obtain viable and accurate information, understand the problem,
establish reasonable goals, and assess the costs and benefits associated with the
problem.
The second skill, the generation of alternative solutions, is the process of
generating as many reasonable options as possible. When this task is done efficiently,
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individuals minimize their reliance on heuristics or old pattel11ed responses of
problem-solving and maximize effective solutions using creativity. The generation of
altel11ative solutions is rooted within tlu'ee primary principles: quantity, affirmative
judgment, and variety. The first is the quantity principal, which states that the more
solutions generated increase the probability that an effective solution will be
produced. Second, the affil1llative judgment principle is the idea that sound solutions
are not more likely to occur when individuals have the time to process their thoughts
during the problem-solving task. Third, the variety principal states that the production
of a broad range of ideas enables the problem solver to generate multiple strategies in
attempts to solve the problem. After several strategies have been considered, the
problem solver is more equipped to na11'0W the list of possible solutions.
The third skill, decision making process, refers to choosing the best possible
solution from the pool of generated ideas. The main objective here is to utilize a cost
benefit analysis to determine the utility of each alternative. During this stage, the
individual engages in a cost-benefit analysis by examining temporal factors, affective
considerations, predicted consequences, and whether the selected solution resolves
the stated problem.
The fourth skill, solution implementation and verification, consists of
assessing if the final outcome meets the anticipated goal. Given the variation among
individual belief systems and interpersonal obligations, the outcome during this step
may require a reevaluation and modification if a more effective solution is deemed
necessary.
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Within the social problem-solving framework, three primary response styles
have been identified. Rational problem-solving is defined as systematic, rational, and
thoughtful methods skillfully applied to problematic situations. This skill set enables
individuals to find adaptive solutions or effective coping responses to specific
problems. Impulsive or careless style occurs when problem solving is conducted in a
haphazard or unsystematic way. For example, the problem-solving approach tends to
be impulsive, careless, hUlTied, and incomplete. Avoidant style is the absence of
solving problems either by choice or due to the lack of identifying a problem exists.
For example, the problem-solving approach often consists of passivity,
procrastination, and a reliance on others' problem-solving abilities to address the
problem at hand.

Social problem solving and depression.
The social problem-solving model examines how individuals approach every
day problems and stress. More specifically, do individuals use constructive or
unconstructive strategies to address everyday problems and stress. Researchers have
been studying the relationship between the components that comprise social problem
solving and the impact it has on psychological distress and depression across the life
span (Nezu, Nezu, Saraydarian, Kalmar, & Ronan, 1986; Nezu, 1987; Nezu & Ronan,
1988; D'Zurilla, Chang, Nottingham, & Faccini, 1998; Reinecke, DuBois, & Schultz,
2001).
In a study by Nezu et al. (1986), the investigators hypothesized that social
problem solving moderates negative stressors and depression and that problem
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solving abilities account for the variation when predicting symptoms of depression
beyond negative stressors. Four hundred sixty-two undergraduate students emolled in
introductory level courses completed the Beck Depression Inventory (a self-report
depression inventory), the Life Experiences Survey (a measure identifying perceived
stress levels secondary to major life changes), and the Problem Solving Inventory (a
measure assessing problem-solving behavior and attitudes). Using a multiple
regression analysis, researchers determined that in individuals confronted with
negative life events, effective problem solvers tended to present with better coping
abilities and were less likely to experience depressive symptoms, while ineffective
problem solvers were identified as more likely to experience depressive symptoms
secondary to negative life events. The authors suggest social problem solving be
considered an important factor when explaining reactive depression subsequent to a
major life event. As such, if ALS is considered a major life event, further exploration
of social problem-solving skills in ALS patients may be predictive of coping abilities
and depression.
In another investigation, Nezu and Ronan (1988) examined social problem
solving as a moderator of stress linked to depressive symptoms using a prospective
analysis. One hundred fifty undergraduate and graduate students voluntarily
completed the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, &
Erbaugh, 1961), the Life Experience Survey (Sarason, Jolmson, & Siegel, 1978), the
Problem Solving Inventory (Heppner & Peterson, 1982), and the Means End
Problem-Solving procedure (Platt & Spivack, 1975). This study concluded: (a)
effective problem solvers were less likely to experience depressive symptoms as a
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result of negative life events, whereas ineffective problem solvers are more likely to
experience depressive symptoms resulting from major negative life events; (b) social
problem solving predicted future distress in individuals experiencing negative life
events and; (c) problem-solving therapy can be used as an effective coping approach
when contl'onted with stress. Since the subject pool was comprised of students with
no lmown medical histories, further research examining social problem solving as a
moderator of stress and depressive symptoms with the ALS population is needed.
Priester and Clum (1993) replicated previous research findings (Nezu &
Ronan, 1988) in order to reexamine the association between problem-solving
appraisal and depression, hopelessness, and suicidal ideation. Three hundred thirty
nine college freshmen were recruited for participation. Pmiicipants were asked to
complete the Beck Depression Inventory, Beck Hopelessness Scale, the Modified
Scale for Suicidal Ideation, the Problem Solving Inventory, and the Life Experiences
Survey prior to taking an examination and again after finding out their grade on the
examination. Results from this study sUPPOlied previous research findings (Nezu &
Ronan, 1988) that problem-solving appraisal was a moderator of stress/depression
and stress/hopelessness when stress was measured by examination grade. The
investigators concluded that a relationship exists between perceived problem-solving
ability, depression, and hopelessness but not suicidal ideation.

Social problem solving and depression in medical populations.
Individuals diagnosed with chronic medical conditions, such as vision
impail1nent, diabetes, cancer, spinal cord injury, and the human immunodeficiency
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virus (HIV) which is the cause of the acquired immunodeficiency syndrome (AIDS),
are often confronted with unique experiences such as psychological distress,
behavioral demands/restrictions, drug treatments regime, and overall lifestyle changes
during the course of medical treatment. The emotional and behavioral reaction styles
and problem-solving abilities across individuals can vary greatly.
Dreer, Elliott, Fletcher, and Swanson (2005) investigated social problem
solving and its relationship to emotional distress, depressive symptoms, well-being,
overall functional abilities, and possible gender differences in 45 subjects diagnosed
with vision impairment (macular degeneration, cataracts, glaucoma, diabetic
retinopathy, and optic nerve atrophy). Each subject completed the Social Problem
Solving Inventory - Revised: Short, the Tactile Analogue Scales, the Center for
Epidemiological Studies Depression Scale, the Satisfaction with Life Scale, and a
modified version of the National Eye Institute Visual Function Questionnaire.
The investigators concluded: negative problem orientation was associated
with emotional distress and depression, and rational problem-solving skills were
positively correlated with life satisfaction. This finding suggests that individuals with
vision impairment tend to be better adjusted when they possess sufficient problem
solving skills, higher levels of motivation, increased treatment adherence, and the
ability to follow through on daily tasks. The results from this study propose using
social problem-solving framework when assessing psychological distress and
functional abilities in individuals with medical conditions. Replication of this study
with ALS patients would provide perspective on emotional distress, depression, and
overall functioning abilities when problem orientation (positive or negative) and
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problem-solving style (rational problem solving, impulsive/careless style, and
avoidant style) are examined.
In another study, 542 Black patients with type 2 diabetes were examined to
determine if a relationship exists between social problem solving in glycemic control
and health behaviors (Hill-Briggs et aI., 2006). Subjects completed the Social
Problem-Solving Inventory - Revised: Short, the Hill Bone Compliance Therapy
scale, a measure to assess medication adherence, the Atherosclerosis Risk in
Communities/ Baecke Leisure Time Activity Scale, a measure of routine engagement
in physical activity, the Center for Epidemiologic Studies of Depressed Mood Scale, a
single item question to assess self-monitoring of blood glucose, and blood via
venipuncture. Results from the study concluded: (1) a normal distribution of social
problem solving across Black patients with type 2 diabetes, (2) problem orientation
and rational problem-solving style was not associated with health behaviors and
glycemic control, (3) ineffective problem solvers were identified with an
impulsive/careless style, while decreased glycemic control was identified with
avoidant style, and (4) avoidant style was associated with variations found in blood
sampling.
The researchers concluded a relationship exists between ineffective problem
solving styles and glycemic control, while no significant relationship was determined
with problem orientation or rational problem-solving style. In addition, problem
solving styles may be a predictor of glycemic control in diabetic patients.
Generalizability of these findings to the ALS population could provide valuable
prevention/intervention strategies. For example, conducting efficacy research in

SPS and ALS 35
order to examine problem orientation and rational problem solving abilities in ALS
patients may facilitate the development of effectively addressing treatment adherence
issues.
In another investigation, Glasgow, Fisher, Skaff, Mullan, and Toobeii (2007)
explored problem-solving skills in a culturally diverse sample of 506 diabetic
sUbjects. The researchers hypothesized that problem solving was associated with self
management, diet, emotional distress, and depression across etlmic groups. The
results from this study did not suggest a significant relationship between patient
characteristics (race/ethnicity, gender, or level of education) and self-management
behaviors. The investigators also found problem-solving abilities of individuals with
diabetes were associated with disease-related distress and depressive affect. This
study demonstrates that problem-solving ability likely plays a role in disease-related
distress and depression. While the clu'onicity of diabetes and potential for physical
limitations is somewhat similar to ALS, future studies specific to ALS patients would
afford more understanding of the mechanism that maintains emotional distress and
depression.
Nezu et al. (1999) conducted two separate investigations to examine various
aspects of the association between problem-solving ability and levels of distress in
cancer patients. In the first study, researchers studied the relationship between
problem solving and distress of cancer patients. One hundred and five recently
diagnosed cancer (breast, leukemia, non-Hodgkin's lymphoma, colon, ovarian,
cervical, prostate, bladder, and rectal) patients being treated at both inpatient and
outpatient oncology depmiments within an urban medical center emolled in the study.
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Each subject completed the Social Problem-Solving Inventory - Revised, Brief
Symptom Inventory, and the Cancer Rehabilitation Evaluation System Form. Study 1
concluded a significant relationship between effective problem-solving and
psychopathology. In the second study, researchers examined the role of problem
solving in predicting distress in the years following breast surgery in survivors of
breast cancer. Sixty-four breast cancer survivors completed questionnaires including
the Negative Impact subscale in the Life Experiences Survey and the Social Problem
Solving Inventory - Revised. Study 2 concluded that high scores on the Negative
Problem Orientation and Rational Problem-Solving subscales of the Social Problem
Solving Inventory - Revised found significant distress in their sample. Outcome
fIndings fl'om both studies were able to support the hypothesis that poor problem
solving ability is associated with higher levels of cancer-related distress. Replication
of a study with ALS patients could provide an understanding of the association
between problem-solving ability, coping, and ALS-related distress.
Elliott (1999) studied the relationship between social problem-solving
abilities, psychological adjustment, and physical health among individuals with recent
onset spinal cord injury cunently enrolled in an inpatient medical rehabilitation
program. More specifically, the researcher examined: (a) problem orientation and
acceptance of disability, (b) the association between problem orientation and career
decisional needs following discharge, and (c) whether problem solving skills predict
the rate of pressure sores 1 year following discharge from the program. One hundred
eighty-six subjects diagnosed with tetraplegia, paraplegia, and lower spine injuries
completed the Inventory to Diagnose Depression, the Social Problem-Solving
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Inventory - Revised, the Acceptance of Disability Scale, the Career Factors Inventory
and received a physical examination by a psychiatrist to determine the presence of
pressure sores. Findings from this study suggest acceptance of a physical disability
includes cognitive, affective, and motivational components often identified in those
with a positive problem orientation. The researcher also determined that disabled
individuals with impulsive or careless problem-solving styles were less likely to
accept their prognosis as compared to those with a more rational problem-solving
style. Replication ofthis study with ALS subjects would provide an understanding of
the role of problem-solving abilities and its association, if any, with psychological
distress.
In another investigation, Jolmson et al. (2006) examined antiretroviral therapy
(ART), a highly effective treatment to decrease HIV -relatedmOliality, to determine
the influence, if any, among treatment adherence, social problem solving, and
psychosocial health. Moreover, this study examined components of problem
orientation and problem-solving styles. Eight hundred sixty-seven subjects completed
the Social Provisions Scale, Beck Depression Inventory, Positive States of Mind
Scale, Social Problem-Solving Inventory - Revised, ART Adherence survey, and a
demographic questionnaire. Researchers concluded: (a) a constructive problem
solving style was associated with more favorable psychological adjustment and
treatment adherence in HIV positive individuals, (b) a dysfunctional problem-solving
style was associated with less than optimal psychological adjustment and treatment
adherence, and (c) poor problem solving was associated with psychological distress
and poor treatment adherence. Generalizability of these results may provide an
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understanding of how patients problem solve through issues related to ALS. In
addition, this study offers a direction to examine further what type of problem-solving
interventions could be used to improve medication adherence.
Presently, there are no known studies on problem orientation or problem
solving styles in the ALS population. As such, future investigations examining the
role of social problem solving, physical functioning, and depression in ALS patients
is needed.

Summary
The literature review provides an overview of ALS and includes other
psychosocial factors associated with the disease. Factors consistently associated with
ALS include physical functioning (Rabkin et al., 2000; Robbins et al., 2000;
Hillemacher et al., 2004; Neudert, 2004), psychosocial considerations (Nelson et al.,
2003), adaptation (Trail et al., 2004), coping (Young & McNicoll, 1998; Mock et al.,
2004; Trail et al., 2004), emotional distress (Trail et aL, 2004), and depression
(Ganzini et al., 1998; Rabkin et al., 2000). One factor that has yet to be examined in
ALS patients is social problem solving. Research already exists on social problem
solving in other chronic medical patients with vision impairment (Dreer et al., 2005),
diabetes (Hill-Briggs et al., 2006; Glasgow et al., 2007), cancer (Nezu et al., 1999),
spinal cord injury (Elliott, 1999), and HIV (Jolmson et al., 2006), among others. As
such, the relationships between depression, social problem-solving skills, and
physical functioning in ALS patients are important to examine to effectively address
depression in this population.
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Hypotheses

This study examines the relationship between social problem solving, physical
functioning, and depression in ALS patients. Specifically, this study aims to test the
following hypotheses:
1. There is a positive correlation between poor social problem solving and
depression;
2. There is a negative but small correlation between physical functioning
and depression;
3. The interaction between social problem solving (positive problem
orientation, negative problem orientation, and rational problem
solving) and physical functioning will significantly predict unique
variance in depression.
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Chapter 2
Method
Participants

The present research utilized data collected from a larger study of ALS
patients focusing on quality of life in patients who attended appointments at ALS
specific multidisciplinary clinics nationwide. Three clinics located in rural or urban
Pennsylvania and Minnesota collected data on the variables examined, indicating
social problem solving, physical functioning, and depression in this study.
Inclusion criteria for each participant consisted of: age 18 years or older;
diagnosis of definite, probable, or probable laboratory-supported ALS; fluency in
English at the sixth grade level or higher; and capable of providing informed consent.
Exclusion criteria for patients consisted of: YOlUlger than 18 years old; the presence
of dementia and or other cognitive impairments, as detected by a physician or
psychologist; and a lack of or refusal to sign informed consent.
The demographic data consisted of: gender, age, etlmicity, marital status, level
of education, household income, and employment status. Other information such as
onset of illness, living a11'angement, and psychotropic medication use was also
obtained.
A total of71 subjects from urban (63.4%) or rural (23.9%) Pennsylvania and
Mhmesota (12.7%) participated in the study. The sample of ALS patients reflected
more males (n = 47,66.2%) than females (n = 24,33.8%) and a mean age of 60.72
(SD = 10.22). The etlmic composition of the ALS subjects included White (n = 63,

88.7%), Black (n = 4,5.6%), Hispanic (n =3, 4.2%) and other (n = 1, 1.4%). Most
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participants were married (n = 52, 73.2%). The participants scored a mean of 4.64
(SD = 1.87) across eight levels of education. Thus, the average ALS patient

completed "some college" or "2 year college degree." The annual household income
ranged from $20,000 to $39,999 (n = 22,31 %), $40,000 to $59,999 (n = 17,23.9%),
$80,000 or greater (n

=

11, 15.5%), less than $20,000 (n

=

6, 8.5%), or "prefer not to

answer" (n = 6,8.5%). The majority of ALS subjects were retired (n = 35,49.3%),
while the remainder were on disability (n = 21,29.6%), were employed full-time (n =
9, 12.7%) or part-time (n = 3, 4.2%), or retired and on disability (n = 1, 1.4%).
The duration of illness for participants ranged from 1 year to 21 years (n = 59;
M= 5.10, SD = 3.85) while the remainder were unknown (n = 12). A greater

proportion of the ALS subjects in the sample lived with their spouse/partner (n = 51,
71.8%), followed by living alone (n = 8, 11.3%), living with a relative (n = 6, 8.5%),
living in a long-term care facility (n = 4, 5.6%), or living with a friend or other (n = 4,
2.8%). Lastly, many of the ALS subjects were not taking psychotropic medication (n
=

28,39 %), while the remainder were taking one or more psychotropic medications

such as an SSRI, bupropion, quetiapine, benzodiazepine, duloxetine, or mirtazapine
(n = 24,34%), or the psychotropic medication detail was unknown (n = 19,27%).

Measures

Demographic information (see Appendix C) from the larger study in
conjunction with various specific questionnaires was completed by study participants
orally or by pointing or blinking while the data collector circled their responses. One
measure assessing muscle strength was completed by the physician and/or medical
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stafT. All of the questionnaires were completed during the participants' scheduled
clinic appointments and were administered in a set order.

P hysical functioning.

Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS 
R) is a 12-item self-report questiOlmaire assessing noticeable physical abilities in
activities of daily living in ALS patients (Cederbaul11, 1999). The domains on the
ALSFRS-R include gross motor abilities, fine motor abilities, and bulbar and
respiratory function. More specifically, some examples of physical abilities assessed
by the questiOlmaire include: speech, salivation, swallowing, dressing and hygiene,
walking, and respiratory insufficiency. Each of the item responses are scored using a

oto 4 point scale, ranging from normal functioning to inability to carry out task on
own. Outcome scores are calculated by adding the up the points endorsed for each
item. Composite totals in the upper limits indicate a higher level of functioning than
scores in the lower limits. The internal consistency values were. 73 for raw and. 71
for standardized. The questionnaire also has good construct validity. Administration
time is approximately 5 to 10 minutes. For purposes of this study, the ALSFRS - R
total score and the three questions assessing bulbar flUlction (speech, swallowing, and
salvation) were analyzed.

Physical strength.

Manual Muscle Strength Test (MMT) measures strength in four muscle
groups (arm abductors, wrist extensors, hip flexors, and ankle dorsiflexors) in both
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the upper and lower extremity muscle groups on the left and right side (Her Majesty's
Stationary Office, 1976). Strength is scored using a 0 to 5 scale (weakest to strongest,
respectively) for each of the muscle groups. Scores are detel111ined by adding up the
total score and dividing by 8. The MMT is an objective measure administered by a
physician and/or medical sta±Ito validate subjective ratings obtained in the ALSFRS 
R.

AjJect.
Brief Symptom Inventory - 18 (BSI - 18) is an 18-item self-report inventory
intended to detect the presence of psychological distress and psychiatric disorders in
medical populations over the age of 18 (Derogatis, 2001). The questiOlU1aire assesses
psychiatric symptoms on tlu'ee dimensions comprised of somatization, depression,
and anxiety. Symptoms are scored using a 0 to 4 scale ranging from not at all to

extremely distressing and scored by adding up the numbers endorsed for each item.
Some example items from the depression dimension include "feeling no interest in
things," "feeling lonely," "feeling blue," "feeling of worthlessness," "feeling hopeless
about the future," and "thoughts of ending your life." The Global Severity Index
represents the overall level of distress and is calculated by adding up total scores on
each dimension. Internal consistency for the tlu'ee dimensions ranged from. 74 to .89.
Internal consistency on the depression dimension was .84. Test-retest reliability
research has yet to be conducted on the BSI - 18. However, the estimated
comparisons from the Brief Symptom Inventory CBSI) are considered to be within a
sufficient range. The BSI test-retest reliability for the General Severity Index was .90
and the depression dimension was .84 CDerogatis, 2001). Initial research outcomes
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found the BS1 - 18 was highly correlated with the Symptoms Checklist 90. The BS1
18 takes approximately 5 minutes to complete. For purposes of this study, the
depression dimension of the BS1 - 18 was used in the data analysis.

JvIood.
The Center for Epidemiologic Studies Depressed Mood Scale
(CES-D) is a 20-item self-report questionnaire initially created for epidemiology
research measuring depression in nonclinical and psychiatric populations (Radloff,
1977). Symptoms are scored using a 0 to 3 scale ranging from rarely or none ofthe
time (less than 1 day) to all ofthe time (5-7 days). Some sample questions include "I
felt depressed," "I had trouble keeping my mind on what I was doing," "I thought my
life had been a failure," "I was happy," and "I enjoyed life." Depression levels are
determined by reverse scoring items 4,8, 12, and 16 and adding the scores on these
and the remainder of items on the questionnaires. Scores range from 0 to 60, with a
score of 16 or higher indicating depressive symptoms. The questionnaire has an
internal consistency of .85 for the nonclinical population and .90 for psychiatric
populations. Split-half and Spearman-Brown reliability coefficients ranged between
.77 and .92, and test re-test reliability was .51 to .67 over a 2 - week to 2- month
period. The CES-D also has good concurrent validity. Administration time is
approximately 5 minutes.
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Social problem solving.

The Social Problem-Solving Inventory -Revised: Shmi (SPSI - R: S)
(D'Zurilla, Nezu, & Maydeu-Olivares, 2002), a 25-item brief questiOlU1aire, assesses
an individual's ability to identify and learn adaptive solutions to everyday living
problems. The SPSI - R: S has two domains: (1) Problem-Solving Orientation is
comprised of two subscales each with five items: Positive Problem Orientation
("Whenever I have a problem, I believe it can be solved") and Negative Problem
Orientation ("I feel nervous and unsure of myself when I have an important decision
to make"), (2) Problem-Solving Style is made up oftlu'ee subscales each with five
items: Rational Problem Solving ("When I have a decision to make, I try to predict
the positive and negative consequences of each option"), Impulsivity and
Carelessness Style ("I am too impulsive when it comes to making decision"), and
Avoidant Style ("I spend more time avoiding my problems than solving them").
Scores are determined by using a 0 to 4 Likeli scale ranging from not at all true ofme
to extremely true. Each scale and subscale has a standardized mean of 100 and a
standard deviation of 15. The scores are added and then converted in standard scores.
Scores of 145 or greater are considered extremely above norm group average and
scores 55 or below are considered extremely below norm group average. The internal
consistency ranged £l'om .60 to .90, test-retest reliability ranged from .68 to .91, and
the standard error of measurement of the standard scores ranged from 3.00 to 9.49.
FurthemlOre, the SPSI - R: S is highly correlated with the Social Problem-Solving
Inventory Revised: Long (SPSI - R: L). The questi01U1aire possesses sufficient
structural, predictive, convergent, and discriminate validity. Administration time is
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approximately 10 minutes. For purposes of this study, the SPSI - R: S total score and
its subscales Positive Problem Orientation, Negative Problem Orientation, Rational
Problem Solving, Impulsivity/Carelessness Style, and Avoidant Style were analyzed.

Design and Procedures
This study was a cross-sectional design that examined the relationship
between social problem solving, physical functioning, and depression in ALS
patients. The data were analyzed using correlation coefficients and a multiple
regression analysis to test the study's three hypotheses.
The following procedures were standardized from a larger ALS quality of life
study. On the day of the ALS patient's regularly scheduled appointment, the potential
participants were informed about the research being conducted at the clinic and were
asked for their voluntary participation. The information about the larger study was
conveyed verbally by health care professionals, including physicians, nurse
practitioners, research coordinators, and volunteer staff, and through a flyer
distributed in the clinic to potential subjects.
When an ALS patient expressed interest in the study, one of the individuals
assigned to collect data went into the examination room after the patient had already
met with his/her physician. At that time, the data collector described the study in
more detail. Patients who agreed to voluntarily participate were asked to sign the
consent form in order to proceed (see Appendix A). When a caregiver was present in
the examination room, he/she was asked to wait in the waiting area lUltil the data
collection process was complete. The data collectors were comprised of master's
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level and advanced doctoral students in clinical psychology f1'om the Philadelphia
College of Osteopathic Medicine, clinic nurses, or other research assistants. Data
collection occurred under the supervision of a clinical psychologist or physician. Each
individual data collector was required to follow a standardized protocol and was
provided written instruction in addition to observing a trained data collector.
Seventy-one ALS subjects participated in the study during one of their
scheduled clinic appointments in a hospital-affiliated setting located in urban or rural
Pe1msylvania or Mhmesota. Patients recruited for this study completed questionnaires
about physical functioning, mood, and social problem solving responding orally, by
pointing, or blinking. In addition, one measure assessing muscle strength was
completed by the physician and/or medical stafT during that same clinic appointment.
These pmiicipants represented a convenience sample. Pmiicipation in this study was
voluntary and no financial compensation was provided. The study was open to
patients across all stages of the ALS illness.
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Chapter 3

Results
The purpose of this investigation was to examine the relationship between
social problem solving, physical functioning, and depression in ALS patients. Data
were initially inspected to evaluate the normalcy of the variables. The analyses for
this study were conducted using SPSS software version 16.0.

Descriptive Statistics
The Social Problem Solving Inventory - Revised Short (SPSI - R: S) assesses
an individual's ability to identify and learn adaptive solutions to problems in
everyday living. Scores are determined by using a 0 to 4 Likert scale ranging from not

at all true olme to extremely true. The scores are added and then converted to
standard scores. Scores of 145 or greater are considered extremely above norm group
average and scores 55 or below are considered extremely below norm group average.
Each scale and subscale has a standardized mean of 100 and a standard deviation of
15. The means and standard deviations for the SPSI - R: S total score were
categorized by age group. The age distributions of ALS subjects in this study were:
young adults (YA) ages 17 to 39 (2.8%), middle age adults (MA) 40 to 55 (42.3%),
and elderly adults (EA) ages 60 to80 (54.9%).
In this sample, SPSI - R: S scores ranged from 64 to 131; means (with
standard deviations in parentheses) for YA, MA, and EA were 104.5 (24.75),102.63
(11.67), and 106.0 (15.15), respectively. The YA ALS sample was difficult to
compare with the normative sample as a result of having a small sample size (N = 2).
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After comparing the ALS subject samples scores on the SPSI - R: S total score to the
age adjusted normative scales, no significant differences were found between the
samples.
Results from the tlu'ee subscales of the SPSI - R: S included Positive Problem
Orientation (PPO) had a mean score of 106.03 (SD = 15.88), with a low score of 63
and a high score of 135. The subscale Negative Problem Orientation (NPO) had a
mean score of96.14 (SD = 15.59), with a low score of78 and a high score of 141.
The mean score on the Rational Problem Solving subscale (RPS) was 104.80 (SD =
14.01), with a low score of 58 and a high score of 137. The subscale Impulsivity
Carelessness (ICS) had a mean score of 100.90 (SD = 13.37), with a low score of 77
and a high score of 137. The mean score on the Avoidance Scale (AS) was 101.10

(SD = 16.85), with a low score of 76 and a high score of 157. Higher scores are
indicative of more effective problem-solving abilities.
The Center for Epidemiologic Studies Depressed Mood Scale (CES - D)
measures depression innonclinical and psychiatric populations. Symptoms are scored
using a 0 to 3 scale ranging from rarely or none o/the time (less than once a day) to
all the time (5-7 days). The mean score was 13.25 with a standard deviation of9.06.
Twenty-five percent ofthe sample scored 6 or less and 75% scored 18.75 or higher.

In this sample, approximately 32.3% of subjects scored within the clinically
significant range.
The Brief Symptom Inventory 18 (BSI - 18) assesses psychological distress
and psychiatric disorders in adult medical populations. For this study, only the
depression subscale was utilized. This measure is scored using a 0 to 4 scale ranging
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from not at all to extremely distressing. The lowest score was 0 and the highest score
was 23. A higher score reflects an increased tendency for depressive symptoms. Raw
scores were converted to T-scores, based on the manual. The n01111S provided for
oncology patients indicate that T -scores of 63 or above are clinically significant
(Derogotis, 2001). In the sample, ALS subjects had a mean raw score of3.49 (SD =
4.35) which is equivalent to a T-score of 54. There were no significant differences
between the ALS sample and the normative sample. Twenty-five percent of the ALS
sample scored 0, and 75% ofthe sample scored above 4. A raw score of 4 is
equivalent to aT-score of 58. In this sample, approximately 15% of subjects scored
within the clinically significant range.
The Manual Muscle Test (MMT), a measure of physical strength, was
administered by a physician and/or medical staff to measure strength on the left and
right side muscle groups (arm abductors, wrist extensors, hip flexors, and ankle
dorsiflexors). Strength is scored on a 0 to 5 scale from weakest to strongest. The
lowest score was .50 and the highest score was 5.00. The mean was 3.70 (SD = 1.10).
On the Amyotrophic Lateral Sclerosis Rating Scale - Revised (ALSFRS - R),
both a composite measure of physical functioning and a score reflecting only bulbar
function (speech, swallowing, and salivation) were used. This scale is scored using a

oto 4 scale ranging iI-om n01111al functioning to an inability to cany out a task
independently. The lowest score was 14 and the highest score was 48 on the ALSFRS
- R total score, with a mean score of 31.84 (SD = 7.42). On the bulbar functioning
subscale, the scores ranged from 1 to 12, with a mean score of9.77 (SD = 2.32). A
higher score means a greater level of physical functioning.
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Hypothesis 1
There is a positive correlation between poor social problem solving skills and
depression.

The hypothesis was supported, and there was, in fact, a positive correlation
between poor social problem-solving skills and depression. The first hypothesis was
evaluated using Pearson product-moment correlation (Pearson r) in order to
demonstrate the strength and direction of the relationship between the variables
(George & Mallery, 2003). The Pearson correlation coefficients were computed
between social problem solving as measured by the Social Problem Solving
Inventory-Revised Short: (SPSI - R: S) total score and the Positive Problem
Orientation (PPO), Negative Problem Orientation (NPO), Rational Problem Solving
(RPS), Impulsivity and Carelessness Style (ICS), and Avoidance Style (AS) subscales
and depression as measured by the Center for Epidemiologic Studies Depressed
Mood Scale (CES - D) and the depression dimension subscale from the Brief
Symptom Inventory 18 (BSI - 18).
The correlation matrix is presented in Table 1. The table illustrates that both
the SPSI - R: S total score, NPO, and ICS are significantly correlated with both
depression measures. All values were evaluated using a significance level of .05 and
were two-tailed. The SPSI - R: S total score is significantly negatively correlated
with the CES - D (r

=

-.41,p < .01). The NPO sub scale is significantly positively

correlated with the CES - D (r = .52, P < .01). The ICS is significantly positively
correlated with the CES - D (r = .25, P = .38). Similarly, the SPSI - R: S total score is
significantly negatively correlated with the BSI - 18 depression dimension
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(1' = -.58,p < .01). The NPO is significantly positively correlated with the Bsr - 18
depression dimension (1' = .34, p <. 01). The rcs is significantly positively correlated
with the Bsr - 18 depression dimension (r =.26, p = .32). Therefore, higher levels of
depression are related to lower levels of social problem-solving abilities and higher
NPO and rcs scores. Also, as seen in Table 1, there was no signifIcant c011'eiation
between PPO, RPS, AS and the depression measures, although the correlation
between the PPO and the CES - D approached signifIcance (r = -.23,p = .06).

Table 1. Correlation Coefficients (I) of},leasurements and Subscales
2

",)

4

5

6

7

8

1. SPSI-R:S a

1.00

0.43**

-0.58**

0.44**

-0.41 **

-0.58**

0.23

0.18

2.PPO

0.43**

1.00

-0.29*

0.67**

-0.23

-0.08

0.02

0.03

3. NPO b

-0.58**

-0.29*

1.00

-0.21

-0.04

-0.19

-0.21

l.00

-0.13

0.15

-0.04

4. RPS
5. CES-D

0.44**

0.67**

0.52**

0.34**
-0.08

-0.41**

-0.23

0.52**

-0.13

1.00

0.76**

-0.10

-0.26*

0.58**

-0.08

0.34**

-0.08

0.76**

l.00

-0.14

-0.22

6. BSI-18
Depression
7. MMT c

0.23

0.02

-0.04

0.15

-0.10

-0.14

l.00

0.61 **

8. ALSFRS-R

0.18

0.03

-0.19

-0.04

-0.26*

-0.22

0.61 **

l.00

Note. *p < .05, **p < .01
a/1

= 70

bn

= 71

en = 69
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Hypothesis 2
There is a negative but small correlation between poor physical functioning and
depression.

The second hypothesis was once again evaluated using Pearson product
moment correlation (Pearson r). The Pearson correlation coefficients were computed
between physical functioning as measured by the Amyotrophic Lateral Sclerosis
Functional Rating Scale - Revised (ALSFRS - R) composite score, a separate score
derived from three questions measuring bulbar function from the ALSFRS - R, and
depression as measured by the Center for Epidemiologic Studies Depressed Mood
Scale (CES - D) and the depression dimension subscale from the Brief Symptom
Inventory 18 (BSI - 18).
Correlation coefficients and significance levels are presented in Tables 1 and
2. Once again, all analyses were two-tailed and evaluated at the .05 level. The
ALSFRS - R was significantly negatively correlated with the CES - D (r = -.26, P
<.05). The correlation between the ALSFRS - R and the BSI - 18 depression
dimension was approaching significance (r

=

-.22, p

=

.07). This result suggests that

as physical abilities decline, depression levels increase. This finding, however, was
only significant on the CES - D. As seen in Table 2, the correlations between the
bulbar functioning sub scale, CES - D, and BSI - 18 depression dimension were not
significant. Overall, there was partial support for hypothesis 2 in that a significant
correlation between poor physical functioning and depression as measured by the
CES - D was demonstrated. However, no significant correlation was found between
poor physical functioning and depression as measured by the BSI - 18. Additionally,
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bulbar function (speech, swallowing, and salivation) was not significantly correlated
with either depression measure.

Table 2.
Correlation Coefficients (r) ofBulbar Function and Depression (n

1

2. BSI-18 Depression

0.76**

3. ALSFRS-R Bulbar

0.10

71)

2
0.76**

1. CES-D

=

3
-0.10
0.03

0.03

Note. *p < .05, **p < .01

Hypothesis 3
The interaction betvveen social problem solving (positive problem orientation,
negative problem orientation, and rational problem solving) and physical
functioning will significantly predict unique variance in depression.

A multiple regression analysis was conducted to evallJ-ate if social problem
solving moderated the relationship between physical functioning and depression.
Multiple regression analysis examines the relationship between two or more predictor
(independent) variables and a criterion (dependent) variable (George & Mallery,
2003). For hypothesis 3, the subscales Positive Problem Orientation (PPO), Negative
Problem Orientation (NPO), and Rational Problem Solving (RPS) from the Social
Problem Solving Inventory-Revised: Short (SPSI - R: S) and the Amyotrophic
Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS - R) were used as the
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predictor variables and depression as measured by the Center for Epidemiologic
Studies Depressed Mood Scale (CES - D) was used as the criterion variable. The
conelation coefficients are presented in Table 1.
All predictor variables were entered into the regression analysis using a
forward method. By virtue ofthe forward method, variables were entered one at a
time. The model is complete when there are no additional variables that explain a
significant portion of additional variance. The NPO was the only variable that met
entry requirements, whereas PPO, RPS, ALSFRS - R and the interaction between
NPO and physical function did not. The overall regression was significant (R 2 = .27,
adjusted R2 = .26, F (1,67)

=

24.56,p <.001). The ~ values indicate the relative

influence of the entered variables with the negative problem orientation as the
variable exerting the most effect,

~=

.52. This model predicts 26.8% of the variance

in CES - D. The multiple regression analysis results suggest that a negative problem
orientation (e.g., when confronted with a problem, it could be perceived as a threat
and may respond with avoidance or poor motivation to address the problem) predicts
a significant proportion of levels of depression. Since the CES - D was not related to
the SPSI - R: S subscales, other than NPO, and the SPSI - R: S scales wer~ not
related to the ALSFRS - R, testing for a moderator relationship was not indicated.
This hypothesis, therefore, was not supported.

Summary ofFindings

A total of 71 ALS patients responded verbally, pointing, or by blinking to
complete a demographic questionnaire (see Appendix C), the Social Problem Solving
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Inventory - Revised: Shmi (SPSI - R: S), the Center for Epidemiologic Studies
Depressed Mood Scale (CES - D), the Brief Symptom Inventory - 18 CBSI - 18)
depression dimension, and the Amyotrophic Lateral Sclerosis Functional Rating Scale
- Revised CALSFRS - R).
In conclusion, the SPSI - R: S total score, NPO, and ICS are significantly
correlated with both depression measures. The ALSFRS - R was significantly
correlated with CES - D. NPO was the only variable predicting a significant amount
of variance in the CES - D. This means that the correlation between poor physical
functioning and depression disappears when NPO is controlled for. Therefore, the
bivariate correlation between physical functioning and depression is entirely
accounted for by the association of poor physical functioning and NPO, rather than a
direct association between physical functioning and depression. NPO was not a
moderating variable between physical functioning and depression.
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Chapter 4
Discussion

This study examined the relationship between social problem solving,
physical functioning, and depression in ALS patients. Specifically, it was sought to
determine if physical functioning predicts depression and if so, whether there was an
interaction between social problem-solving skills, physical functioning, and
depression. Three specific hypotheses were explored to answer these questions. Two
of the three hypotheses were supported by the data. This chapter will address the
following findings: (a) clinically significant levels of depression were found in 15 
32.3% of the ALS subjects, (b) there was a positive correlation between poor social
problem solving skills and depression, (c) there was a small correlation between poor
physical functioning and depression, (d) bulbar functioning was not correlated with
depression, and (e) negative problem orientation predicted 26.8% ofthe total variance
for depression.

Conclusions

In the current study, 32.3% of the subjects reported with clinically significant
levels of depression as measured by the CES - D and 15 % of subjects reported with
clinically significant levels of depression on the BSI - 18 depression dimension. The
outcome scores on both depression instrwnents portrayed a positively significant
correlation with one another (I' = .76,p < .01). This correlation suggests the
instruments measured the same construct. The levels of depression as evidenced by
the sample were consistent with prior studies that reported lower levels of depression
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among ALS patients (Ganzini et ai. 1999; Rabkin et aI., 2000). The current study
found that 33.8% of ALS subjects were prescribed psychotropic medications, while
Rabkin et ai. (2000) reported only 16%. It is not clear whether these patients in the
current study had a preexisting history of depression, if they were prescribed a
psychotropic medication on or after disease onset, or whether subjects who endorsed
depressive symptoms were taking a psychotropic medication.
Also, both GallZini et ai. (1999) and Rabkin et ai. (2000) documented
depression in approximately 10% of their samples, while the current study found
approximately 15-32.3 % ALS subjects reported depression, One explanation for
these differences is that in both the Ganzini and Rabkin studies, depression was
assessed using objective measures, rather than subjective reports, as used in this
investigation. Another potential explanation for the discrepancies in depression
ratings may be related to the plu'asing of the questions used with ALS patients. For
instance, in Rabkin et aI.' s (2000) study, celiain questions were omitted from the
depression scales regarding sleep problems, poor appetite, and psychomotor
retardation. The researcher's rationale for this was to minimize the misinterpretation
between symptoms related to ALS and depression.
The first hypothesis was suppOlied and found a positive correlation between
poor social problem-solving skills and depression. More specifically, a robust
correlation between negative problem orientation and depression was found.
Although there are no known studies that conelated social problem solving and
depression in ALS patients, there is empirical suppOli for the relationship between
depression and social problem solving with other populations (Nezu, 1987). Also,

SPS and ALS 59
social problem-solving abilities have been associated with optimal levels of
adjustment following chronic disease (Elliott, Grant, & Miller, 2004).
Consistent with the current study, other investigations have documented
similar findings that negative problem orientation was predictive of depression (Nezu
et aI., 1999; Elliott et aI., 2004; Dreer et aI., 2005; Johnson et aI., 2006; Glasgowet
aI., 2007).In one investigation, Dreer et al. (2005) documented that negative problem
orientation was predictive of emotional distress and elevated depression scores in
vision impaired patients. Nezu et al. (1999) concluded that effective problem-solving
was associated with lower levels of depression and that negative problem orientation
was significantly correlated with distress in cancer patients. Elliott et al. (2004) found
that effective problem solvers tended to be more psychologically adjusted toward
living with a chronic medical condition. Johnson et al. (2006) demonstrated that
dysfunctional problem- solving style was associated with poorer psychological
adjustment in HIV subjects, which accounted for compromised treatment adherence.
Finally, Glasgow et al. (2007) concluded poorer problem-solving ability was
associated with disease-related distress and depression.
Another finding in the cunent study was the low correlation between
Impulsivity and Carelessness style and depression. The current study was consistent
with the finding from a study conducted by Elliott (1999) demonstrating that
impulsivity/carelessness style was associated with decreased levels of acceptance of a
spinal cord injury prognosis. Hill-Brigg et al. (2006) also found an association
between CES - D scores, Impulsivity and Carelessness style, and glycemic control in
type 2 diabetics. One explanation for this finding may be due to the larger sample size
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or the nature of the chronic medical conditions examined in each of these
investigations as compared to the current study.
The supported t1ndings in hypothesis 1 suggest problem-solving abilities may
influence coping in ALS patients. These results are seemingly consistent with theories
of coping (Lazarus & Folkman, 1984; D'Zurilla & Nezu, 1999) and its relationship
with depression in that it suggests cognitive, affective, and behavioral processes
influence coping style. For example, in the relational model of stress, coping
appraisal is an important aspect in determining how an individual copes (Lazarus &
Follmlan, 1984). Similarly, in the relational/problem-solving model of stress, problem
solvilig plays a signitIcant role as a general coping strategy (D'Zurilla & Nezu, 1999;
D'Zurilla, Nezu, & Maydeu-Olivares, 2004). In the coping literature (Tobin et al.,
1989; Livneh & Antonak, 2005) for individuals with chronic illness and/or
disabilities, individual coping strategies have been described as both adaptive and
maladaptive based on specit1c coping characteristics such as locus of control, affect
regulation, cognitions, and behavior. Though the current study did not examine
specit1c characteristics of coping, the study found that poor problem-solving coping
predicted higher levels of depression. These t1ndings might better be understood
when conceptualized within the constructs of the social problem-solving model as
aspects of either a positive or negative problem orientation. A negative problem
orientation produces negative emotions, avoidance, unproductive worry, diminished
effOli, and low motivation, while a positive problem orientation tends to produce
positive emotions, focus, effort, motivation, persistence, and frustration tolerance, and
allow for unceliainty. Accordingly, ALS patients with a negative problem orientation
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have the propensity to experience hopelessness, social isolation, loss, and feelings of
being physically out of control. Rabkin et al. (2000) examined factors of hopelessness
in ALS patients using the Beck Hopelessness Scale, a measure used to assess three
aspects of hopelessness (feelings about the future, loss of motivation, and
expectations). The study concluded that intensity of hopelessness contributed to the
30% of ALS patients who experienced moderate depression and 13% that
experienced severe depression. Additionally, Plahuta et al. (2002) concluded an
extemallocus of control and an absence of meaning in life was a predictor of
hopelessness in ALS patients.
Therefore, the ability to improve ALS patients' positive problem orientation is
an important consideration in order to enhance adaptive coping. Young and McNicoll
(1998) demonstrated that ALS patients who were able to cope well with the disease
were found to possess optimism, humor, adaptive cognitive strategies, and utilize a
strong support network. Hecht et al. (2000) demonstrated that adaptive coping
included religiosity and family support. Finally, Mock et al. (2004) found ALS
patients who were able to give up control were more optimistic and less depressed.
Overall, it seems that the use of cognitive-behavioral methods of treating depression
by focusing directly on negative problem orientations may be of great benefit to ALS
patients.
The second hypothesis was paliially supPOlied and found there was a small
con-elation between poor physical functioning and higher depression. This outcome
suggests that as general physical abilities decline, depression levels increase. This
relationship was only seen when using the CES - D alld not with the BSI - 18. As
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previously mentioned, the elevated scores on the CES - D in the current study might
be better explained by the phrasing of some of the questions which could apply to
symptoms of depression and/or symptoms related to ALS.
Consistent with the current study, Hogg et al. (1994) found that poor physical
functioning was associated with higher levels of depression, although other studies
have found no relationship between physical functioning and depression (Rabkin et
aI., 2000; Robbins et aI., 2001; Norquist et aI., 2003; Hillemacher et aI., 2004). One
explanation may be related to the selection of measures used to assess depression as
seen in Rabkin et aI. (2000). In their study, subjects were administered measures such
as the Patient Health QuestiOlUlaire, an instrument developed for medical populations
that assesses for the nine DSM-IV criteria, and the Beck Depression Inventory. During
the scoring process, three items related to sleep problems, poor appetite, and
psychomotor agitation were omitted, as these symptoms are sometimes considered to
be directly caused by ALS. This could lead to lower depression scores. Another
possible explanation for the inconsistent findings may be that in Robbins et al. 's
(2001) study, psychological factors were assessed using general quality of life
(McGill Quality of Life questiOlUlaire) and ALS-specific health-related quality of life
(SIP/ALS-19) instruments rather than a depression-specific measure. Moreover, in an
investigation conducted by Norquist et al. (2003), the subject pool was comprised of
918 subj ects spanning 15 countries across Europe, while the current study had 71
ALS pmiicipants, all of whom resided in urban or rural Pennsylvania or Minnesota.
European cultural differences may have influenced different results as compared to
urban and rural Pennsylvania and Minnesota. Although the current study found a
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correlation between declining physical function and depression, there may be other
influences that also account for depression. Other studies have addressed disease
related stressors, which could have a greater impact on depression beyond physical
functioning. Trail et aI. (2004) concluded that illness progression and dependency on
others, problems speaking, and muscle weakness were their greatest concems. This
suggests other variables, such as receiving the formal diagnosis of ALS by a
nelU'ologist (Gallagher & Momoe, 2006), age of disease onset, or ALS and its overall
impact on life roles (Kingsnorth, 2006), or coping and adaptation skills to manage
lifestyle changes (Hecht et aI., 2002; Young & McNicoll, 1998) could all potentially
influence a negative mood state. The current study did not entirely account for all of
these outside inf1uences.
Another consideration may be that the sample in the ClU'rent study was not as
physically impaired as subjects in the other investigations. In the cunent study, the
mean score and standard deviation on the ALSFRS - R was 31.84 (SD = 2.32) as
compared with other studies reporting mean scores and standard deviations of 24.7
(SD = 9.3) (Hillemacher et aI., 2004) and 23.3 (SD = 7.8) at baseline and 17.1 (SD =

6.7) at time two (Rabkin et aI., 2000). One explanation for the differences in scores
could due to the variability of disease progression and stage of illness of ALS
participants in the respective investigations.
The current study examined the relationship between bulbar fl.U1ctioning and
depression and did not find a significant correlation. The cunent study was
inconsistent with other investigations (Goldstein et aI., 2006; Hillemacher et aI.,
2004) that demonstrated a significant correlation between bulbar functioning (e.g., the
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ability to verbally communicate with others, chewing and swallowing food to sustain
nutritional balance, and being able to control saliva and drooling), breathing, and
reactive depression. Neither study, however, found decreased bulbar functioning and
higher levels of depression over time. Respiratory insufficiency was not analyzed
separately in this study. Though there is no cure for symptoms related to bulbar
functioning, prior research suppOlis the idea that depression symptoms should be
monitored as impairment occurs in the bulbar regions (Goldstein et al., 2006).
The third hypothesis stated the interaction between social problem solving
(positive problem orientation, negative problem orientation, and rational problem
solving) and physical functioning would predict unique variance in depression. In the
CU11'ent study, only negative problem orientation emerged as a significant predictor of
depression in ALS patients. Negative problem orientation predicted 26.8% of the total
variance for depression as measured by the CBS - D. By contrast, no significant
associations were demonstrated by positive problem orientation or rational problem
solving.
Furthermore, the CU11'ent investigation was not able to test for a moderator
relationship. While other investigations have yet to examine the moderating role of
social problem solving in the ALS population, prior research (Nezu & Ronan, 1985;
Nezu, 1986; Nezu & Ronan, 1988) has established social problem solving as a
moderator of the negative effects of stressful major life events on depression. This
suggests a need for future research to continue to examine the role of social problem
solving in the ALS population.
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In conclusion) the examination of the three hypotheses made two
contributions to the literature. First) this study appears to be one ofthe first to
examine the role of social problem solving in ALS patients. Second) results from this
current study found negative problem orientation to be a predictor of higher levels of
depression) rather than decreased physical functioning in ALS patients.

Study Implications
This investigation makes an impOliant contribution to the literature in that it is
among the first to examine the relationship between social problem solving) physical
functioning) and depression in ALS patients. The outcome of this investigation
strengthens the finding that a negative problem orientation) not physical function) is a
predictor of higher levels of depression in ALS patients. This finding proposes the
usefulness of problem solving therapy (PST) for ALS patients. PST is an empirically
supported, formal treatment approach which has been used to treat depression in other
chronically ill medical populations such as cancer patients (Nezu) Nezu) Felgoise)
McClure, & Houts, 2003).
PST can be modified for ALS patients in order to help reduce depression that
is associated with deficits in problem-solving ability. The rationale for selecting PST
is to help ALS patients to identify and resolve disease-related stressors that are
influencing maladaptive responses and at the same time teach general skills training
to adaptive responses to solve problems. Furthermore, since depression not only
affects the ALS patient but also influences the family, an integral part of effective
work with ALS patients should include their caregiver and/or family members. In
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SUppoli of this concept, Murphy (2003) identified a positive relationship between
problem solving and quality oflife/psychological distress in caregivers of ALS.
Though the premise of this current study was not examining caregivers or family
members, their inclusion in PST could positively influence the problem orientation
(motivation level) and problem-solving skill acquisition of the ALS patient. In a
cancer population, inclusion of caregivers in PST proved to be beneficial in
maintenance of gains from PST training (Nezu et al., 2003). This generally occurs by
the caregiver and/or family member's willingness to make accommodations in the
social environment and provide ongoing suppOli during varying phases of ALS
(Vuchinich, 2004).
The application of PST occurs tlu'ough two processes: (a) problem orientation
which is a motivational component, and (b) problem-solving proper, which is the
method by which the ALS patient would explore adaptive solutions to speciflc
problems through the use of problem-solving strategies. First, the problem-orientation
process within social problem solving is a set of responses that influences cognitive,
behavioral, and affective responses in the presence of a stressful situation or problem.
A positive problem orientation tends to produce positive emotions, focus, effc)1i,
motivation, and persistence, frustration tolerance, and allow for uncertainty.
Altematively, negative problem orientation produces negative emotions, avoidance,
unproductive worry, diminished effort, and low motivation. PST emphasizes specific
p1'Oblem orientation variables consisting of: problem perception, problem attribution,
p1'Oblem appraisal, personal control beliefs, and approach avoidance style. Two
examples of ALS patients with a negative problem orientation are described. In
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example one, problem appraisal may occur when receiving the news of the initial
diagnosis. At this time, the ALS patient may appraise the problem as being diagnosed
with ALS. This problem may lead toward feelings of hopelessness that without a
known cure, negative predictions may be generated about his/her future of living with
the disease. In example two, perceived control through a negative problem orientation
lens is defined as possessing low self-efficacy, viewing problems as difficult,
threatening, and lacking motivation to confront the problem. An ALS patient
experiencing ongoing decreased physical abilities such as difficulty com11lunicating
may determine this problem is not solvable and as a result engage in maladaptive
problem solving by avoiding attempts to ameliorate the conmlUnication problem.
The next process in PST includes teaching four problem-solving skills to
maximize thoughtful problem solving in order to determine the most effective
solution to a particular problem. These four problem-solving skills are: problem
definition and formulation, generation of altemative solutions, decision making, and
solution implementation and verification. In general, PST is facilitated by enhancing
motivation in order to utilize the effective problem-solving skills and to promote high
self-efficacy in the process.
In summary, treatment goals could focus on: (a) improving ability to
recognize the presence of a problem, (b) reducing the influence of emotional distress
and negative thought pattems, (c) developing a perspective that uses a systematic
approach to problem solving to provide a means of effective coping, (d) aiding in the
development of expecting successful coping abilities, and (e) refraining from the
temptation of reacting impulsively or avoiding the problem. Clinical psychologists
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and other mental health care professionals can provide psychoeducation, treatment
plmming, and implementation of PST to ALS patients as well as their caregiver
and/or family member for the duration of the disease.
Furthermore, the role of a clinical psychologist on the multidisciplinary team
may prove valuable for a variety of reasons. First, they could provide ongoing
assessment of cognitive changes, coping strategies, and mood incongruence. Second,
they are able to assess for depression and provide referrals to other mental health
professionals such as psychiatrists for dual treatment along with psychotherapy and
pharmacotherapy, ifrecommended. Third, they would be able to improve
conm1Unication between medical staff and ALS patients in order to address any
ongoing concerns the ALS patients may have regarding their medical treatments.

Limitations ofStudy
Several limitations were identified in the current investigation. The lllU11ber of
individuals in the sample was small (N = 71), contributing to a potentially decreased
statistical power. Other studies examining social problem solving and psychological
distress in medical populations with c1u'onic conditions used samples with over 500
subjects (Hill-Briggs et aI., 2006; Jolmson et aI., 2006; Glasgow et aI., 2007).
However, it is important to note that these studies were not examining patients with
ALS, but rather patients with other chronic medical conditions who tend to
experience more symptom variability, treatment options, and greater life expectancy.
Though limited by the sample size, the current study does provide valuable
information on the effects of social problem-solving abilities mld depression in ALS.
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Another study limitation was that pmiicipant recruitment consisted of patients
receiving treatment at one of three ALS hospital-affiliated clinics located in rural
(63.4%) or urban (23.9%) Pelillsylvania or Minnesota (12.7%). Also, the majority of
subjects in the sample were White (88.7%). Therefore, these results may be difficult
to generalize to other ethnicities or geographical regions.
Another limitation of this study includes the use of self-repOli measures to
assess problem-solving skills and depression. This use of subjective measures versus
objective measures places great emphasis on the ALS patient's perceived rather than
actual state.
Even though this study documented subjects who were prescribed a mood
stabilizing medication at the time of data collection, information regarding the
patients' history of depression prior to ALS onset was not lmown.
Another limitation of this study was not obtaining a coping history of ALS
subjects. Clinically, this infoTInation is often considered to be predictive of one's
ability to adjust to lifestyle changes.
Finally, this study did not account for the number of potential subjects who
declined participation. Patients often schedule their clinic appointment with their
multidisciplinary treatment teams approximately four times a year. During these
visits, patients often expect to remain in the clinic for a few hours. The combination
of physical symptoms as a result of ALS and general fatigue might have played a role
in the limited number of patients who volunteered to participate in the study.
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Future Directions

Future studies of ALS patients could consider the following changes in the
design of the study or other areas for further investigation: First, when studies are
limited to just one group, the generalizability to all groups is low. Future studies
would be better if they included a larger sample size of ALS patients with more
ethnic minorities from diverse parts of the country.
Second, subject recruitment may pose a challenge due to the nature and course
of ALS. Future studies may want to assess reasons for nonparticipation in order to
develop alternative data collection approaches. For instance, telephone interviews or
home visits may be an alternative method of ensuring greater participation in research
studies from ALS patients.
Third, coping patterns of ALS patients tend to influence depression levels.
Future investigations may benefit from obtaining a history of specific coping patterns
in ALS patients across stages of the disease.
Fourth, the ALS patients' perceived social support from caregivers, spouse,
family, and friends may also impact depression levels. Future investigations may
consider examining aspects of these relationships and their association with
depression.
Fifth, depression is an important construct to examine in ALS patients as it
influences cognitive and emotional coping responses. Future investigations could
benefit from obtaining a detailed history of depression, which may prove to be useful
for group comparison research. Additionally, using both subjective and objective
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measures (e.g., clinical interviews, Structured Clinical Interview for DSM-IV
Disorders) may reflect more precise levels of depression in ALS patients.
Lastly, there seems to be a gap in the literature regarding empirically
supported treatments for depression in ALS patients. Future investigations examining
the application of problem-solving therapy, a standaJ.'clized treatment model, to
address potential cognitive and coping skill deficits may prove to be an impOliant
approach for treating depression in ALS patients.
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Department of Neurology, R037
500 University Drive, P.O. Box 850
Hershey, PA 17033-0850

David C. Good, MD
Chairman: Department of Neurology
Phone: (7171531-1803

Tel: (717) 531-8692
Fax: (717) 531-4694
Appt: (717) 531-1441·
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Dear ALS Clinic Patient:

You may be familiar with our studies of quality of life and have participated in
Clinical Neurophysiology
them in the past. Based on our results to date, we are beginning a new study on
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Epilepsy Program
and there is no additional ~ost to you.
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Enclosed you will fmd a consent form. Please look at this, and bring it with you to
clinic. If you choose to participate, we will explain the study in more detail, .
answer any questions which you may have, obtain your signature on the consent
form, and conduct the interview.
Your participation is entirely voluntary. We would like you to consider
participation in this study. If you have any questions about this research study, you
may contact me at 717-531-1802, or you may contact the Research Coordinator,
Beth Stephens, at 717-531-0003, ext. 283395.

Sincerely,

Zachary Simmons, MD
Professor and Vice-Chair ofNeurology
Director, Neuromuscular Program & ALS Clinic
This research study has been approved by the Institutional Review Board, under federal
regulations, at Penn State Milton S. Hershey Medical Center (IRB No: 21184EP)
Version Date: 6/20/2005

An Equal Opportunity University
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Title of Project: Measuring Quality of Life in Individuals with Amyotrophic Lateral
Sclerosis and their Caregivers: Patient Consent Form
Principal Investigator: Zachary Simmons, MD
,

,

Other Investigators: Kevin Scott, MD, Helen E. Stephens, MA, Susan Walsh, RN ,
McKenzie Walker, Diana Brown, Andrea Weller

,Participant's Printed Name: _ _ _ _ _ _ _ _ _ _ _ __
this is a research study. Research studies include only people who want to take part.
This form gives you information about this research, which, will be discussed with you. It
may contain words or procedures that you don't understand. Please ask questions
about anything that is unclearto you. Discuss it with your family and friends and take
your time to make your decision,

1. Purpose of the Research:
You are being offered the opportunity to take part in this research because you are an
individual who has been diagnosed with amyotrophic lateral sclerosis (ALS).
The purpose of this, research is to better understand those factors which contribute to
quality of life iriindividuals with ALS,and to use this information to develop a brief,
accurate questionnaire for future use. This questionnaire will be specifically designed to
evaluate quality of life in individuals with ALS.
This is a multi-center study that is occurring at 9 university-affiliated ALS clinics.
Approximately 280 people will take part in this'research nationwide and 40 people are
expected to take part at the Hershey Medical Center.

2.

Procedures to be Followed:

If you consent to this study, then at one of yourALS clinic appointments, you will be asked
to complete series of questionnaires or be interViewed about your physical limitations,
emotions, coping abilities, values, interests, desires, goals, the ~upport that you receive
from others, and the role of refigion in your life: These 'questionnaires will also include

a
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questions on the impo.rtance of emotional intimacy (sharing deep, private thoughts; feeling
connected), physical intimacy (for example, touching, hugging, kissing), and sexual
intercourse on your quality of life, although you will not be asked for the names or
- relationships of others with whom you share such intimacy. You are free to skip any
questions that you would prefer not to answer. If you become fatigued while completing
the questionnaire, you may take short breaks.
The questionnaire will be administered by an advanced doctoral student in clinical
psychology from the Philadelphia College of .osteopathic Medicine, the institution that is
coordinating this multi-center study. This information will be collected only once, and will
take 50 minutes of additional time beyond the usual time needed .for your ALS clinic
appointment. If there is information missing from the questionnaire, you may receive a
phone call from one of the investigators to request complete information.
Information will be collected from your medical record about your neurological disorder.

3.

Discomforts and Risks:

There is no physical discomfort, and there are no physical risks associated with this
study. You may experience emotional discomfort and become upset due to thinking
about how all these factors impact on your life with ALS. You may decline to respond to
a particular question or a questionnaire,' but you may be asked by an investigator why
you chose not to respond.
You may experience fatigue. You may request breaks as needed. You may also stop your
'. participation in answering the questionnaire at any time.

4. Possible Benefits:
a. Possible benefits to the participant:
Your doctors may develop a better understanding of those factors that affect your
. quality of life, and may be able to use this information to improve the quality of your
existence. However, no benefit is guaranteed.

b. Possible benefits to others:
This study may lead to a better understanding of those factors which affect the quality of
life in other patients with ALS, and may lead to the development of a questionnaire that
accurately assesses this for other persons with this disease.
5. Other Options that Could be Used Instead of this Research:
You do not have to take part in this research study.

6. Time Duration of the Procedures and Study:
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If you agree to take part in this study, your involvement will last approximately 50
minutes. You may receive a phone call to confirm answers when some of the
information on the questionnaire is incomplete. The phone call will take a few minutes.

7.

Statement of Confidentiality:
a. Privacy and confidentiality measures

Your research records that are reviewed, stored, and analyzed at The Milton S. Hershey
Medical Center '(HMC) and Penn State College of Medicine (PSU) will be kept in a locked
file in the office of Dr. Zachary Simmons in the Department of Neurology, or on a
password-protected computer file accessible to Dr. Simmons and to Beth Stephens, the
co<!>rdinator of the study.
For research records sent to the Philadelphia. College of Osteopathic Medicine, you will not
be identified by name, social security number, address or phone number. The records will
include 'a code number. The list that matches your name with the code number will be kept
in a locked file in Dr. Simmons' office or on a password-protected computer file accessible
to Dr. Simmons.
In the event of a.ny publication or presentation resulting from the research, no personally
. identifiable information will be shared.

7b. The use of private health information:
Health information about you will be collected if you choose to be part of this research
study. Health information is protected by law as explained in the HMC Privacy Notice. If
you ha.ve not received this notice, please request a copy from the researcher. At The
Milton S. Hershey Medical Center (HMC) and Penn State College of Medicine (PSU) your
information will only be used or shared as explained and authorized in this consent form or
when required by law. It is possible that some of the other people/groups who receive your
health information may not be required by Federal privacy laws to protect your information
and may share it without your permisSion.
To participate in this research you must allow the research team to use your health
information. If you do not want us to use your protected health information, you may not
participate in this research.
Your permission for the use, retention, and sharing of your identifiable health information
will expire upon completion of the research study. At that time the research information
not already in your medical record will be destroyed. Any research information in your
medical record will be kept indefinitely.
If you choose to participate, you are free to withdraw your permission for the use and
sharing of your health information at any time. You must do this in writing. Write to Dr.
Simmons and let him know that you are withdrawing from the research study. His mailing
address is:
Zachary Simmons, MD,
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Department of Neurology, H037
Penn State Milton S. Hershey Medical Center
500 University Drive
Hershey, PA 17033.
If you withdraw your permission:
• We will no longer use or share medical information about you for this research
study, exCept when the law allows us to do so.
• We are unable to take back anything we have already done or any information
we have already shared with your permission.
• We may continue using and sharing the information obtained prior to your
withdrawal if it is necessary for the soundness of the overall research.
• We will keep our records of the care that we provided to you as long as the law
requires.
The research team may use the following sources of health information.
•
•

Information from your medical records about your neurological disorder
The information you provide during the questionnaire inteiview

. Representatives of the following people/groups within HMC/PSU may use your health
information and share it with other specific groups in connection with this research
study.
• The principal investigator, Dr. Zachary Simmons
• The HMC/PSU Institutional Review Board
III
The HMC/PSU Human Subjects Protection Office
lit
Members of the research team
The above people/groups may share your health information with the following
people/groups outside HMC/PSU for their use in connection with this research study.
These groups, whHe monitoring the research study, may alsO review and/or copy your
. . .
original PSU/HMC records.
• The Office of Human Research Protections in the U. S, Department of Health
and Human Services
III

•

Stephanie Felgoise, PhD, Philadelphia College of Osteopathic Medicine, a
co-investigator of this study.
The advanced doctoral students in clinical psychology at the Philadelphia
College of Osteopathic Medicine who are data collectors for this study.

8. Costs for Participation:
You will not experience extra expense for participation in this study.
You are not waiving any legal rights you may have by signing this form.

9. Compensation for Participation:
You will not receive any compensation for being in this research study.
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10. Research Funding:
This institution and the investigators are not receiving any funds to support this research
study.
11. Voluntary Participation:
'Taking part in this research study is voluntary. If you choose to take part in this research,
your major responsibilities will include completing a questionnaire. You do not have to
participate iil this research. If you choose to take part, you have the right to stop at any
time. If you decide not to participate or if you decide to stop taking part in the research at a
later date, there will be no penalty or loss of benefits to which you are entitled. Your
medical care will not be affected.
12. Contact Information for Questions or Concerns:
You have the right to ask any questions you may have 'about this research. If you have
questions or concerns ,or believe you may have developed an injury that is related to this
research, contact Dr. Simmons at 717-531-1802.
,If you have questions regarding your rights as a research participant or you have concerns
or general questions about the research or about your privacy and the use of your
personal health information, contact the research protection advocate in the HMC Human
Subjects Protection Office at 717-531-5687. You may also call this nurnber if you cannot
rea'ch the research team or wish to talk to someone else.
For more information about participation in a research study and about the Institutional
Review Board (IRB), a group of people who review theresearchto protect your rights,
please visit the HMC IRB's Web site at http://www.hmc.psu.edu/irb. Included on this web
site, under the heading "Participant Info", you can access information about the protection
of human research participants. If you donothaveaccess to the internet, copies of these
regulations are available bycalling the HSPO at (717) 531-5687.
, Signature and Consent/Permission to be in the Research
, Before making the decision regarding enrollment in this 'research you should have:
• Discussed this study with an investigator,
• Reviewed the information in this form, and
• Had the opportunity to ask any questions you may have.
Your signature below means that you have, received this information, have asked the
que~tions you currently have about the research and those questions have been
answered. You will receive a copy of the Signed and dated form to keep for future
reference.
Participant: By signing, this consent form, you indicate that you are voluntarily choosing to
take part in this
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Signature of Participant

Date

Time

Printed Name

Person Explaining the Research: Your signature below means that you have
explained the research to the participant/participant representative and have answered
any questions he/she has about the research.

Signature of person who explained this research
Date
Time
Printed Name
(Only approved investigators for this research may explain the research and obtain informed
consent.)
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Department of Neuro)ogy

~ University of P~nnsylvania Health System

Spring/Summer, 2006

Dear ALS Clinic Patient:
You may be familiar with our studies of quality of life and have participated in them'in
the past. Based on our results to date, we are beginning a new study on quality of life in
individuals with ALS. The current study is also being conducted at 8 other ALS centers
across the country. We would greatly appreciate your cooperation in this study., If you
choose to participate, it will require approximately 45-50 minutes of your time in the
. clinic, during which we will ask you a series of questions regarding your quality of life.
No blood tests or other procedures are involved, and there is no additional cost to you.
Enclosed you will find a consent form. Please look at this, and bring it with you to clinic.
If you choose to participate, we will explain the study in more detail, answer any
questions that you may have, obtain your signature, and conduct the interview.
Again, participation is entirely voluntary. However, we believe that this is 'a very
important study, and would greatly appreciate your participation.

Sincerely,

Leo McCluskey, MD

Lauren Elman, :MD

Enclosure

330 South 9th Street· Philadelphia, PA 19107' (215) 829-6500 • Fax: (215) 829-6606

Robert Kalb, :MD

Pennsylvania

J{o~taf

.

Department of Neurology

>.

~

University of Pennsylvania Health System

IRBAPPROVALDATE Id/b 1

JNFORMED CONSENT FORM (patient)
Title:

EXPIRATION DATE /02 /0 (P
.

r

Measuring Quality of Life in Individuals with Amyotrophic Lateral Sclerosis

Sponsor:

Stephanie H. Felgoise, Ph.D., ABPP
Department of Psychology
Philadelphia College of Osteopathic Medicine
4170 City Avenue
Philadelphia, P A 19131
215-871-6543
Investigator: Leo McClus~ey, :MD
Department of Neurology
330 South 9th Street
Philadelphia, P A 19107
215-829-3053

IRB Number:
Participant's name:_ _ _ _-'--_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

PURPOSE
The purpose of this study is to understand what adds to quality oflife in indivi~uals with
Amyotrophic Lateral Sclerosis (ALS), and to use this information to test a brief questionnaire
designed to assess quality of life in individuals with ALS.
The doctors and scientists at Philadelphia College of Osteopathic Medicine (pCOM) do research
on diseases and new treatments. The interview you are being asked to volunteer for is part of a
research proj ect.
Even though this research study is looking at specific aspects of ALS, such as physical
limitations, emotions, coping abilities, values, interests, desires, goals, the support that you .
receive from others, and the role of religion in your life, no one can say that this will improve
your usual treatment.
If you have any questions about this research, you can call Dr. Stephanie Felgoise at (215) 871
6543 or Dr. Leo McCluskey at 215-829-3053.
Version 1,2/7/06
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DESCRIPTION OF THE PROCEDURES
This consent fonn gives you information about the research study. This infonnation·will also be
discussed with you. Once you learn about the study, you will be asked whether or not you would
like to participate. If you would like to participate, you will be asked to sign this fonn. A copy of
this signed fann will then be given to you for your records. If your doctor has diagnosed you.
with dementia, cognitive problems, or if you do not agree to thIs infonned consent, you cannot .
be in this study.. '
.
If you agree to participate in this study, then at one of your ALS clinic appointments, you will.be
asked to complete a series of questionnaires about your physical limitations, emotions, coping
abilities, values, interests, desires, goals, the support that you receive from others; and the ioleof
religion in your life. All questionnaires will be read to you in interview fonn. Also, please ki10w
that you may refuse to respond to a particular que~tion or questionnaire at anytime.
During your participation in the study, you may get tired. If this occurs, you may request breaks
as needed. You may also stop your participation in the study at anytime.
This information will be collected only once, and will take 45-50 minutes of additional time
beyond the usual time needed for your ALS clinic appointment.

POTENTIAL BENEFITS
Your doctors may develop a better understanding of quality of life for persons with ALS. This
study may lead to a future questionnaire that accurately measures quality of life for other persons
with ALS. A questionnaire of this nature will help researchers' and clinicians' to develop
medical and psychosocial interventions according to their patients' needs and be able. to monitor
patient change.
You may not benefit from being in this study. However, other people in the future may benefit
from what the researchers learn from the study.

RISKS AND DISCOMFORTS
There is no physical dis'comfort, and there are no physical risks associated with-this study.
However, you may experience emotional discomfort and become upset due to thinking about
how life has changed with ALS.
.
There are no known risks or discomforts from being in the study.

ALTERNATIVES
Your other choice is to not be in this study and continue with your regular treatment by your
doctor at the ALS clinic without prejudiCe.
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PAYMENT
You will not receive any payment for being in this study.
CONFIDENTIALITY·
All information and medical records relating to your·participation will be kept in a locked file.
Only the doctors, members of the Institutional Review Board, and the U.S. Food and Drug
Administration will be able to look at these records. If the results of this study are published, no
names or other identifying information will be used ..
REASONS YOU MAYBE TAKEN OUT OF THE·STUDY WITHOUT YOUR CONSENT
If health conditions occur that would make staying in the study possibly dangerous to you, or if
other conditions occur that would damage you on your health, your doctor or hislher associates
may take you out of this study. In addition, the entire study may be stopped if dangerous risks or
side effects occur in other people.
NEW FINDINGS
If any new information develops that may affect your willingness to stay in this study, you will
be told about it.
INJURY

If you are injured· as a result of this research study, you will be provided with immediate
necessary medical care.
However, you will not be reimbursed for medical care or receive other payment. Pennsylvania
. Hospital and the UIiiversity of Pennsylvania Health System will not be responsible for any of .
your bills, including any routine medical care under this program or reimbursement for any side
effects that may occur as a result of this program.
If you believe that you have suffered injury Or illness in the course of this research, you should
notify Joseph Sherwin, Ph.D., Director of Regulatory Affairs at the University of Pennsylvania at
(215) 898-2614.
.
VOLUNATRY PARTICIPATION
You may refuse to be in this study. You voluntarily consent to be· in this ~tudy with the
understanding of the !mown possible effects or hazards that might occur while you are in the
study. Not all the possible effects of the study are known.
You may leave this study at any time.
If you drop out of this study, there will be no penalty or loss of benefits to which you are entitled..
Version 1, 217/06
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I have had adequate time to read this fonn and I understand its contents. I have been given a
copy for my personal records.
I agree to be in this research study.
, Signature of Subject: _ _ _---'-_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Printed Name of Subject:_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Date'. ----.......;--
I
I

Signature ofInvestigator or pesignee:_---'_ _--:..._ _ _ _ _ _ _ _ _ _ _ __

Printed Name of Investigator or Designee:_ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Date: - -I
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HENNEPIN
FACULTY
ASSOCIATES
ysl,l.ns 01 Hennepin County Medl,.1 Center

ALSA Certified ALS Center
825 South Eighth Street, Suite 250
Minneapolis, Minnesota 55404
Phone: (612) 347·7635
or
(800) 346·4262
Fax: (612) 347·6183
William S. David, M.D., Ph.D.,
Medical Director
Electromyography
Pamela A. Droberg, R.N., B.S.N.,
Coordinator
Charlotte L. Roehr, M.D.,
Physiatry

,
Conrad Iber, M.D.,
Pulmonology
Oliver W. Cass, M.D.,
Gastroenterology
Mary K. Wiley, R.N.,
Clinic Nurse
Maxine S. Siobof, M.A., C.C.C.·SLp,
Speech· Language Pathology
nald Rowan, R.C.P,
Kespiratory Therapy
Nina L. Ross, L.I.S.W., M.P.H.,
Social Work
Wendy R. Johnson, R.D.,
Nutrition
Elizabeth A. Bartlett, O.T.R./L.,
Occupational Therapy
Sandra L. Swanson, P.T.,
Physical Therapy

Dear ALS Clinic Patient:
Some of you are familiar with our studies of quality of life and have
participated in them in the past (thank you to those of you who have
participated). Based on our results to date, we are beginning a new
study on quality of life in individuals with ALS. The current study is
also being conducted at 8 other ALS centers across the country.
We would greatly appreciate your cooperation in this study. If you
choose to participate, it will require approximately 45-50 minutes of
your time in the clinic, during which we will ask you a series of
questions regarding your quality of life. No blood tests or other
procedures are involved, and there is no additional cost to you.
Enclosed you will find a consent form. Please look at this, and
bring it with you to clinic. If you choose to participate, we will
explain the study in more detail, answer any questions which you
may have, obtain your signature, and conduct the interview.
Again, participation is entirely voluntary. However, we believe that
this is a very important study, and would greatly appreciate your
participation.
.
Sincerely,

Carol J. Ludowese, M.S., c.G.c.,
Genetic Counselor

William S. David, MD, PhD
Medical Director
Hennepin Faculty Associates
ALSA Certified ALS Center

Enclosure
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FACULTY
ASSOCIATES

Physicians of Hennepin County Medical Center

ALSA Certified ALS Center
825 South Eighth Street, Suite 250
Minneapolis, Minnesota 55404
Phone: (612) 347-7635
or
(800) 346-4262 .
Fax: (612) 347-6183

INFORMED CONSENT FORM
TITLE OF STUDY

William S. David, M.D., Ph.D.,
Medical Director
Electromyography

Measuring Quality of Life in Individuals with Amyotrophic Lateral Sclerosis

Pamela A. Droberg, R.N., B.S.N.,
Coordinator

INVESTIGATOR: William S. David, M.D., PhD.

Charlotte L. Roehr, M.D.,
Physiatry

SPONSOR OF STUDY: Philadelphia College of Osteopathic Medicine

Conrad Iber, M.D.,
Pulmonology
Oliver W. Cass, M.D.,
Gastroenterology

PURPOSE

Mary K. Wiley, R.N.,

The purpose of this research is to better understand those factors which
contribute to quality of life in individuals with amyotrophic lateral sclerosis
(ALS), and to use this information to validate a brief, accurate questionnaire
specifically designed to evaluate quality of life in individuals with ALS. This
study will be conducted in nine ALS Clinics across the United States. Each site
will enroll 30 participants.

Clinic Nurse
Maxine S. Siobol, M.A., e.e.e.-SLP,
Speech - Language Pathology
DonaId Rowan, R.C.P,
Respiratory Therapy
Nina L. Ross, L.1.5.W., M.P.H.,
ocial Work
Wendy R. Johnson, R.D.,
Nutrition
Elizabeth A. Bartlett, O.T.R./L.,
Occupational Therapy
Sandra L. Swanson, P.T.,
Physical Therapy
Carol J. Ludowese, M.S., e.G.e.,
Genetic Counselor

You are being asked to participate in this clinical research study because of your
current health condition. Clinical research is the study of human disease in an
attempt to improve diagnosis and treatment. In order to decide whether or not
you should agree to be part of this research study, you should understand enough
about its risks and benefits to make a judgment. This process is informed
consent.
This informed consent gives you information about the research study that will
be discussed with you. Once you understand the study, you will be asked to sign
this form if you wish to participate. You will be given a copy of this signed form
for your records. If your physician has diagnosed you with dementia, cognitive
impairments, or if you do not agree to this informed consent, you cannot be in
the study.

DESCRIPTION OF THE PROCEDURES
If you consent to this study, then at one of your ALS clinic appointments, you
will be asked to complete a series of questionnaires, you will be interviewed
about your physical limitations, emotions, coping abilities, values, interests,
desires, goals, the support that you receive from others, and the role of religion
in your life.

An Equal Opportunity Employer
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FACULTY
ASSOCIATES

Physicians of Hennepin County Medical Center

ALSA Certified AlS Center
825 South Eighth Street, Suite 250
Minneapolis, Minnesota 55404
Phone: (612) 347-7635
or
(800) 346-4262
Fax: (612) 347-6183
William S. David, M.D., Ph.D.,
Medical Director
Electromyography
Pamela A. Droberg, R.N., B.S.N.,
Coordinator
Charlotte L. Roehr, M.D.,
Physiatry

This information will be collected only once, and will take 45-50 minutes of
additional time beyond the usual time needed for your ALS clinic appointment.
POTENTIAL BENEFITS
Your doctor may develop a better understanding of those factors that affect the
quality of life for people with ALS. However, no direct benefit is guaranteed,
and you may not benefit at all from participation in this study. This study may
lead to further development of a questionnaire that accurately assesses quality of
life for people with ALS. Other people in the future may benefit from what the
researchers learn from this study.

Conrad Iber, M.D.,
Pulmonology
Oliver W. Cass, M.D.,
Gastroenterology

ruSKS AND DISCOMFORTS

Mary K. Wiley, R.N.,
Clinic Nurse

There is no physical discomfort, and there are no physical risks associated with
this study. Yau should understand that you may decline to respond to a
particular question or questionnaire. Y0U may experience emotional discomfort
and become upset due to thinking about how all these factors impact on your life
aith ALS.

Maxine S. Siobof, M.A., e.e.e.-SLP,
Speech - Language Pathology
Donald Rowan, R.C.P,
Respiratory Therapy
Nina L. Ross, L.I.S.W., M.P.H.,
>ocial Work

You may experience fatigue. You may request breaks as needed. You may also
stop your participation in answering the questionnaire at any time. .

Wendy R. Johnson, R.D.,
Nutrition

ALTERNATIVES

Elizabeth A. Bartlett, O.T.R.IL.,
Occupational Therapy
Sandra L. Swanson, P.T.,
Physical Therapy
Carol J. Ludowese, M.S., e.G.c.,
. Genetic Counselor

The other choice is not to be in this study and to have the usual treatment by
your physician at the ALS clinic without prejudice.
PAYMENT
You will not receive any payment for being in this study.
CONFIDENTIALITY
If you consent to participate in this study, you will be authorizing the use of your
private health information for purposes of this study.
By signing this form, you authorize the HFA ALS Clinic and the investigators to
use and disclose any information created or collected in the course of your
participation in this research protocol.
This information may be given to other researchers in this study (including those
at other institutions), representatives ofthe company sponsoring the study, or·
private, state, or federal government parties responsible for overseeing this

An Equal Opportunity Employer
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Physicians of Hennepin Gounty

Medlc~1

Genter

ALSA Certified ALS Center
825 South Eighth Street, Suite 250
Minneapolis, Minnesota 55404
Phone: (612) 347-7635
or
(800) 346-4262
Fax: (612) 347-6183
William S. David, M.D., Ph.D.,
Medical Director
Electromyography
Pamela A. Droberg, R.N., B.S.N.,
Coordinator
Charlotte l. Roehr, M.D.,
Physiatry
Conrad Iber, M.D.,
Pulmonology
Oliver W. Cass, M.D.,

Gastroenterology

research. These may include the Food and Drug Administration, the Office for
Human Research Protection or other offices within the Department of Health
and Human Services, and the Minneapolis Medical Research Foundation Office
for Human Subject Protection.
This information will be given out for the proper monitoring of the study,
checking the accuracy of the study data, analyzing the study data, and other
purposes necessary for the proper conduct and reporting ofthis study. This
authorization lasts until the end of the study. You can, however, revoke it in
writing.
You may stop this authorization at any time except if the HF A ALS Clinic needs
the information already collected to ensure complete and accurate study results.
This might mean the HF A ALS clinic may continue to use your information
collected as part of this study even after you have told them to stop.

Mary K. Wiley, R.N.,
Clinic Nurse
Maxine S. Siobof, M.A., e.e.e.-SLP,
Speech - Language Pathology
Donald Rowan, R.C.P,
Respiratory Therapy
Nina l. Ross, L.I.S.W., M.P.H.,
Jcia! Work
Wendy R. Johnson, RD.,
Nutrition
Elizabeth A. Bartlett, O.:r.R./l.,
Occupational Therapy
Sandra l. Swanson, P.T.,
Physical Therapy
Carol J. Ludowese, M.S., e.G.e.,
Genetic Counselor

REASONS YOU MAY BE TAKEN OUT OF THE STUDY WITHOUT
YOUR CONSENT
If health conditions occur that would make staying in the study possibly
dangerous to you, or if other conditions occur that would damage you or your
health, your doctor or his associates may take you out of the study.
In addition, the sponsor may decide to stop the entire study.

NEW FINDINGS
If any new information develops that may affect your willingness to stay in this
study, you will be told about it..

INJURY
Ifyou are injured as a result of this study, you will be provided with immediate
necessary medical care.
However, you will not be reimbursed for medical care or receive other payment.
Medical services will be given at the usual charge. Your medical treatment will
be billed to your third party payer/insurance or to you.

YOUR RIGHTS IF YOU TAKE PART IN THE STUDY

An Equal Opportunity Employer
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Physicians 01 Hennepin County Medical Center

ALSA Certified ALS Center
B25 South Eighth Street, Suite 250
Minneapolis, Minnesota 55404
Phone: (612) 347-7635
or
(BOO) 346-4262

Fax: (612) 347-6183
William S. David, MD., Ph.D.,
Medical Director
Electromyography
Pamela A. Droberg, R.N., B.S.N.,
Coordinator

You do not have to take part in this study, but if you do, you can stop at any
time. Your medical care at HFA ALS clinic will not be affected now or in the
future whether or not you take part in this study. You do not give up any of your
rights by taking part in this study. You will be told of any new findings or
changes in study procedures that may affect you or your willingness to continue
in the study. lfthe trial results are published, your identity will remain
confidential.
WHO CAN ANSWER YOUR QUESTIONS?

Charlotte l. Roehr, M.D.,
Physiatry
Conrad Iber, M.D.,
Pulmonology
Oliver W. Cass, M.D.,
Gastroenterology
Mary K. Wiley, R.N.,
Clinic Nurse
Maxine S. Slobof, M.A., e.e.e.-SLP,
Speech - Language Pathology
Donald Rowan, R.e.p,
Respiratory Therapy
Nina l. Ross, L.I.S.W., M.P.H.,
Dcial Work

You may talk to Dr. William David, M.D.,PhD. at any time about any question
you have on this study. You may contact Dr. David by calling 612-873-7521.
You may also contact Pamela Droberg, R.N. in the ALS clinic at 612-347-5224.
You can get further information about your rights as a research subject by
contacting the Human Subjects Research Committee at 612-347-8528.

I have had adequate time to read this form. I have read, and to the best of
my knowledge understand, this form. I have been given a copy for my
personal records. I agree to be in this research study and I authorize the use
of the information that is collected for the purposes of this study. By signing
this form, I am not giving up any of my legal rights.

Wendy R. Johnson, RD.,
Nutrition

Signature of Subject:_ _ _ _ _ _ _ _ _ _--'-_ _ _ _ _ _ _ __

Elizabeth A. Bartlett, O.T.RjL.,
Occupational Therapy

Date: -------/
/

Sandra L. Swanson, P.T.,
Physical Therapy

Signature of Witness: ____________________

Carol J. Ludowese, M.S., e.G.e.,
Genetic Counselor

Date:- -/ - -/ - Signature of Investigator or Designee_______________
(circle one)
Date:- -/ - - /- -

An Equal Opportunity Employer

ALS Quality of Life Demographic Sheet
Each of these questions relates to the person with ALS who is enrolled in the current quality of
life study. Please complete each question by writing in the information requested or marking the
single best answer:

Name:

--------------------------------~

SfudyID#: ________________

Gender (choose one):
~---.cMale

Female

----'

Age in years:

Education
_No high school
~Some high school
_High school diploma
Some college
2 year college degree
_4 year college degi-ee
_Graduate degree
Trade/Technical degree
Living Arrangements
_Uvesalone
_With spouse (husband or wife)
With Other relative
_With friend or other person
_Long term care facility
Marital Stafus
Never married
_Currently married
Divorced
_Separated
Widowed

Household Income
_Less than $20.000
_.$20,000 - $39,999
_$40,000 - 59,999
_$60,000 - $79,999
_$80,000 or more
Prefer not to answer

Racial Background
_White/Caucasian
_Hispanic/Latino
Black!African American
_Oriental!Asian Pacific Islander
_Other.
_Prefer not to answer

Employment Status
Currently working?
Yes
_No
If yes
_Part time
Full time
If no
Retired
_Unemployed
_On disability
._Not working outside of the home prior to ALS
MonthlDate When You First Became Symptomatic _ _ _ _ __
When were you first diagnosed with ALS (MonthlYear)? _ _ _ __

Manual Muscle Testing
The following muscle groups are to be tested on both sides
GIl
Arm (shoulder) abductors
CIII
Wrist Extensors
III
Hip Flexors
III
Ankle Dorsiflexors
Grade the strength in each muscle group using the foliowing scale designed by the
Medical Research Council (J\1RC):

o
1
2
3
4
5

No contraction
Flicker or trace of contraction
Active movement with gravity eliminated
Active movement against gravity
Active movement against gravity and resistance
Normal power

For grades 3,4, and 5, these measurements may be modified as "+" and "-" (grade 5 can
be modified only by "-") if power is believed to be slightly greater or lesser than that
described above. In such cases, the modifier changes the whole number by 113 of a grade
for purposes of calculation:
5- is equivalent to 4.67
4+ is equivalent to 4.33
4- is equivalent to 3.67
3+ is equivalent to 3.33
3- is equivalent to 2.67
Measured muscle strength for each muscle group is to be recorded on the attached sheet,
with the average of all 8 measurements then calculated to determine the composite 11RC
score.

Manual Muscle Testing Data Sheet
Subject Name:
Study ID #:
Date:
Muscle Group

MRC Rating: Right

Ann (Shoulder) Abductors
,

Wrist Extensors

Hip Flexors
Ankle Dorsiflexors

Composite MRC Score: _ _ _ _ __

MRC Rating: Left

ALS Functional Rating Scale - Revised
1. Speech

4 Normal speech process
3 Detectable speech disturbance
2 Intelligible with repeating
1 Speech combined with nonvocal communieation
oLoss of useful speech
2. Salivation
4 Normal
3 Slight-but-definite--ex-eess--6f--saliYa in mouth; may1laYe nighttime

drooling
.
2 Moderately excessive saliva; may have minimal drooling
1 Marked excess of saliva wlth-some drooling
oMarked drooling; requires constant tissue or handkerchief
3. SwaUowing

4 Normal eating habits·
3 Early eating problems~occasional chocking
2 Dietary consistency changes
1 Needs supplemental tube feeding
oNPO (exdusively parenteral or enteral feeding)

o

Speech

o

Salivation

o

Swallowing

4. Handwriting

.4Normal
3 Slow or sloppy; all words are legible
2 Not all words are legible
1 Able to grip pen bqt unable to write
oUnable to grip pen
Sa. Cutting Food and·HandIingUtens1ls (patients without gastrostomy)
4 Normal
3 Somewhat slow and clumsy, but no help needed
2 Can cut most foods, although clumsy and slow; some help needed
1 Food must be cut by someone, but can still feed slowly
.0 Needs to be fed

D

Handwriting

D

Cutting Food &
Handling Utensils
Gastrostomy 0

D

Dressing & Hygiene

Sb. Cutting Food and Handling Utensils (alternate stale for patients
with gastrostomy)

4 Normal
3 ClUmsy but able to perform all manipulations independently
2 Some help needed with closures and fasteners
1 Provides minimal assistance to caregiver
oUn/lble to perform any aspects oftask
6. DresSing and Hygiene

4 Normal function
3 Independent and complete self-care with effort or decreased efficiency
2 Intermittent assistance or substitute methods
1 Needs attendant for self care
oTotal dependence

ALS Functional Rating Scale - Revised
-Page2 

7. Turning in Bed and Adjusting Bed Clothes
4 Normal
3 Somewhat clumsy, but no help needed
2 Can turn alone or adjust sheets, but with great difficulty
1 Can initiate, but not tum or adjust sheets alone
oHelpless

D

Turning in Bed &
Adjusting Bed
Clothes

D

Walking.

D

Climbing Stairs

D

Orthopnea

o

Respiratory
Insufficiency

8. Walking
4 Normal
3 Early ambulation difficulties
2 Walks with assistance
1 Nonambulatory functional movement
oNo purposeful leg movement

9. Climbing Stairs
4 Normal
3 Slow
2 Mild unsteadiness or fatigue
1 Needs assistance
o Cannot do

10. Dyspnea
4 None
3 Occurs when walking
2 Occurs with one or more ofthe following:
eating, bathing, dressing (ADL)
1 Occurs at rest, difficulty breathing when either sitting or lying
o Significant difficulty, considering using mechanical respiratory support

11. Orthopnea .
4 None
. 3. Some difficulty sleeping at night dueto shortness ofbr~ath,
does not routinely use more than two pillows
2 Needs. extra pillows in order to sleep (more than two)
1 Can only sleep sitting up
. 0 Unable to sleep

12. Respiratory Insufficiency
4 None
3 Intermittent use ofBiPAP
2 Continuous use ofBiPAP during the night
1 Continuous use ofBiPAP during the night and day
oInvasive mechanical ventilation by intubation or tracheostomy

Total Score

D

Center for Epidemiologic Studies - Depressed Mood Scale (CES-D)
Using the scale provided, indicate the number which best describes how often you felt or behaved this
way-DURING THE PAST WEEK.

DURING THE PAST WEEK:
Rarely or none
of the time (less
than 1 day)

Some ora
little of the
time (1-2
days)

Occasionally
or a moderate
amount of
time (3-4
days)

Most or all
of the time
(5-7 days)

1. I was bothered by things that

usually don't bother me.

0

1

2

3

2. I did not feel like eating; my
appetite was poor.

0

1

2

3

3. I felt that I could not shake off
the blues even with help from
my family and friends.

0

1

2

3

4. I felt that I was just as
good as other people.

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

8. I felt hopeful about the future.

0

1

2

3

9. I thought my life had been a failure.

0

1

2

3

1O. I felt fearful.

0

1

2

3

5. I had trouble keeping my mind
on what I was doing.

6. I felt depressed.
7. I felt that everything I did was
an effort.

Rarely or none
of the time (less
than 1 day)

Some ora
little of the
time (1-2
days)

Occasionally
or a moderate
amount of
time (3-4
days)

Most or all
ofthe time
(5-7 days)

11. My sleep was restless.

0

1

2

3

12. I was happy.

0

1

2

3

13. I talked less than usual.

0

1

2

3

14. I felt lonely.

0

1

2

3

15. People were unfriendly.

0

1

2

3

16. I enjoyed life.

0

1

2

3

17. I had crying spells.

0

1

2

3

18. I felt sad.

0

1

2

3

19. I felt that people dislike me.

0

1

2

3

20. I could not get "going."

0

1

2

3

Derogatis,1. R. (2001). Brief Symptom Inventory 18. NCS Assessments. MiImeapolis:

MN.

Example Questions from Instrument:

How Much Were You Distressed By:
0= Not al all
1 = A little bit
2 = Moderately
3 = Quite a bit
4 = Extremely
Feeling no interest in things

o

1

2

3

4

Feeling lonely

o

1

2

3

4

D'Zmilla, T. J., Nezu, A. M., & Maydeu-Olivares, A. (2002). SOyial Problem-Solving
Inventory-Revised. Technical manual. North Tonawanda, NY: Multi Health
Systems.
Example Questions from Instrument:

o= Not at all true of me
1 = Slightly true of me
2 = Moderately true of me
3 = Very true of me
4 = Extremely true of me
I feel nervous and unsure of myself when
I have an important decision to make

0

1

2

3

4

I spend more time avoiding my
problems than solving them

0

1

2

3

4

